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ABSTRACT OF THE DISSERTATION
DIGITAL PROTEIN ANALYSIS:
TECHNOLOGIES FOR PROTEIN DIAGNOSTICS AND PROTEOMICS THROUGH
SINGLE-MOLECULE DETECTION

by
Lee Aaron Tessler

Doctor of Philosophy in Computational and Systems Biology
Washington University in St. Louis, 2011
Professor Robi D. Mitra, Chairperson

Protein quantification tools are valuable in biological and biomedical research and
in clinical applications because they enable measurements that elucidate physiological
states, including disease states. Protein biomarker detection is likely to play a major role
in patient health and aid in the personalization of medicine. However, protein detection
has lagged behind other bio-analytical methods due to intrinsic properties of proteins as
well as the complexity of biological fluids, such as blood. This thesis describes the
design, development, and testing of several technologies for the advancement of protein
detection in clinical and research settings. A common thread through these technologies
is the isolation of millions of protein molecules on a solid surface, the interrogation of
those molecules by fluorescently-labeled antibodies, and the identification and
quantification of those molecules by single molecule resolution imaging. By
systematically investigating the parameters that have prevented single-molecule
quantification of surface-immobilized proteins, we achieved technologies that can
ii

digitally quantify biomarkers in single-plex and multi-plex formats and be used to detect
protein-protein interactions. Additionally we characterized a surface coating method that
will be of benefit to a wide array of biophysical studies. Finally, we conducted proof-ofprinciple experiments and computer simulations for the development of a highthroughput proteomics technology that relies on only a small set of probes (8 to 50) to
analyze each of the approximately 23,000 human proteins.
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CHAPTER ONE: INTRODUCTION
Diagnostics – the identification and characterization of disease in individuals – is
of critical importance to patient health. Despite the diverse ways that diseases form, be it
by

microbial

infection,

congenital

mal-development,

environmental

exposure,

autoimmunity, genetic background, or combinations of the above factors, all treatment
structures are inextricably linked with diagnosis[1].
Evidence suggests that improving diagnostics in terms of accuracy and early
detection can be sufficient to reduce patient mortality and morbidity. For example,
cervical cancer deaths have been diminished by 74% since the introduction of the Pap
Test which can detect the cancer at an early stage[2]. Notably, the Pap Test was a
tremendous success against cervical cancer despite the fact that it was introduced in 1928
when scientists had little understanding of the molecular basis of the cancer. Disease
detection can save lives even from diseases we know little about[3]. Early detection has
also proven valuable in the fights against heart disease[4], diabetes[5], and other types of
cancer[6-10], so it is likely to be valuable in many diseases.
Not only can early diagnosis greatly improve patient outcomes, but the lack of
early diagnosis can be severely detrimental. Adenocarcinomas are cancers of glandular
tissue epithelia and include colon, breast, and pancreatic cancers. Adenocarcinomas are
curable; with early detection, the five-year survival rates of colon and breast cancers is
over 90% and 95%, respectively (Figure 1)[11]. By contrast, with late detection, those
survival rates are decreased to 8% and 16% respectively. Interestingly, pancreatic cancer,
1

which is an adenocarcinoma for which no early stage test exists and which does not cause
symptoms until late stages, is one of the most fatal cancers with a less than 5% five-year
survival rate[12]. Taken together, high patient fatality rates from adenocarcinomas are
less due to our inability to treat the disease than to the inability to detect the disease until
late stages.
The reason that early diagnosis may be so helpful is the nature of disease
progression. For example, cancer evolves from a small group of cells, becomes more
mature over time, and eventually invades different parts of the body. Detecting a tumor at
an early stage implies that the tumor is likely to be relatively small and localized making
surgical interventions more effective. Early detection also allows more time for various
treatment strategies to be attempted. Thus, the ability to make a diagnosis at an early
stage increases the effectiveness of interventions and increases the number of possible
interventions[13].
How then, can biomedical science accelerate the development of new and better
diagnostic tests? Histological, microbiological and immunohistochemical tests are used
to analyze the characteristics of cells and tissues for disease detection. Molecular and
biochemical tests allow for measurements of nucleic acids, proteins, or metabolites that
are circulating in biological fluids like blood. When these measurements statistically
correlate with disease-state across a wide body of individuals, they are called biomarkers.
Molecular and biochemical biomarkers are especially promising because they are
inherently quantitative and, as opposed to histological methods, enable a view of
biological samples at the resolution at which underlying biochemical mechanisms occur.
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The collection of human proteins is the proteome, and the analysis of the
proteome holds great promise for the discovery of diagnostic biomarkers for several
reasons. Firstly, proteins are the major effectors of the physiology of an organism. The
Central Dogma of Molecular Biology generally holds true in that DNA and RNA act to
produce the appropriate collection of proteins which then carry out cellular functions.
The presence of certain proteins indicates cells in the body are carrying out or are poised
to carry out a particular physiological function. Secondly, protein expression can change
based on environmental and temporal stimulae, so there is a reasonable likelihood that
disease progression may be able to be monitored through routine screenings. Finally, the
proteome is diverse: vastly more diverse than the mRNA which codes it. The abundance
and activation state of each protein depends not only on transcriptional regulation but
splice-form regulation, translational regulation, and post-translational modification[14].
So, protein biomarkers have a greater chance of correlating with physiological states than
genomic or transcriptome biomarkers[13].
With the potential so high for the discovery and application of protein
biomarkers, what has prevented their realization? The main challenge lies in the
measurement of protein abundance, and that is mostly due to the enormous concentration
ranges at which proteins exist in biological samples[15]. After removing cells and
clotting factors from blood, the remaining serum provides enormous potential for finding
biomarkers since it contains blood-specific proteins as well as leakage products from all
of the body’s tissues (Figure 2)[16]. However, proteins in serum exist over a range of ten
orders of magnitude (Figure 3)[17], so when analyzing a serum sample, a protein of
interest may be present at one copy out of ten-billion. This “copy number problem”
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dominates the proteomic technology landscape to such an extent that, whereas, during the
Human Genome Project, the yardstick of technological advancement was “base pairs
sequenced per unit of time,” the yardstick in proteomics is “protein copies per unit
volume.”[18]
Nucleic acid quantification technologies have been able to get around the copy
number problem (e.g. qPCR can detect single DNA molecules via amplification), so why
have similar methods for quantifying proteins lagged behind? For one, there is no protein
analog to PCR, and that prevents low abundance proteins from being amplified to bulk
quantities. Additionally, there is no efficient way to create a molecule that partners to, or
binds to, a protein with high affinity, as there are for nucleic acids (i.e base pair
complementarity). Finally, nucleic acid methods benefit from the fact that all DNAs and
RNAs have similar biochemistry: they are all negatively charged, due to a phosphodiester
backbone. By contrast, proteins have diverse biochemistry in several ways. Amino acids
have vastly different chemical properties, ranging from acidic to basic and from
hydrophobic to hydrophilic. Stretches of similar amino acids can create proteins with
very different bulk properties. Also, proteins are often decorated by post-translational
modifications such as phosphotyrosines, lysines, and polysachharides, which can greatly
affect their charge and hydrophobicity. Thus proteins have proven more difficult to
analyze than nucleic acids, and better molecular tools for detecting proteins are necessary
for advancing disease detection capabilities.
Proteomics and protein diagnostics are currently carried out by two major classes
of technologies, the immunoassay and mass spectrometry[19]. Each of these classes has
their classical applications, which can be found in research laboratories and in clinical
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diagnostic facilities. Additionally, both the immunoassay and mass spectrometry fields
are rife with novel technological variations that enable increased performance in areas
like sensitivity, reproducibility, and multiplexing.
Mass spectrometry operates by the ionization of proteins, the fragmentation of
proteins into peptides, the determination of the mass of the peptides to a high degree of
accuracy, and the comparison of that mass to a database of known peptide masses[20].
This method is often preceded by separating proteins by chromatography to resolve
different proteins within a sample. A notable benefit of mass spectrometry is the ability to
analyze many proteins with three to four orders of magnitude dynamic range.
Additionally, novel mass spectrometric methods have appeared over the last decade that
improve sensitivity and extend dynamic range even further. One promising development
is Selective Reaction Monitoring (SRM) mass spectrometry which operates by training
the instrument on peptides that the experimenter expects to observe in the sample and
extends the dynamic range to five orders of magnitude[21]. Despite the promise of SRM,
the general utility of mass spectrometry is hampered by several issues[22]. Its main
drawback is its inadequately high limit of detection (LOD) which lies at 10-9 M.
Clinically-relevant biomarkers are present in the 10-12 - 10-10 M range in serum. Also,
despite the fifty year legacy of peptide mass spectrometry, it continues to be highly
specialized, needing expert oversight in experimental planning, implementation,
optimization, and data analysis. These are some of the shortcomings that have prevented
mass spectrometry from becoming widely used to screen populations in clinical settings,
where automatability and reproducibility are highly valued.

5

The immunoassay, or antibody-based detection, is the most widespread way for
research and diagnostic laboratories to detect proteins. It relies on the biological
phenomena that antibodies – the molecules that confer immunity for organisms – behave
by binding non-covalently to their target via physical contact points[23]. Antibodies
produced by organisms like rabbits can be isolated from the blood of the rabbits within a
laboratory setting, purified, and used for in vitro studies. The most common research
methods involving the use of antibodies are the Western blot and the enzyme-linked
immunosorbent assay (ELISA). The principle behind both of these is that the antibody is
labeled by a reporter molecule (such as an enzyme that produces a change in the optical
absorbance of a liquid, a fluorophore, or a magnetic particle) and then the labeled
antibody binds to its target if the target is present. After a wash step to remove un-bound
antibody, the amount of the remaining antibody, which is bound to its target, is read by
an appropriate detector such as an absorbance spectrometer, fluorometer, or
electromagnetic sensor. The signal produced by the remaining antibody, (substracted
from a target-less control to account for non-specific binding of the antibody) defines an
analytical measurement of the abundance of the target.
The Immunoassay, and ELISA in particular, is widely use in diagnostics due to its
high sensitivity (LOD down to 10-15 M), practical dynamic range (three to four orders of
magnitude), and automatability. They have been developed into a variety of platforms
that have been shown to improve performance in terms of multiplexing and sensitivity.
One solution to multiplexing the immunoassay has been the development of antibody
microarrays[24]. The main advantage of this technology is that is increases the number of
targets that can be analyzed given a volume of sample. Other technological innovations

6

have included proximity ligation assays[25, 26], bead-based arrays[27, 28], and hybrid
antibody-DNA detection methods[29]. Interestingly however, no immunoassay had been
shown that employed single-molecule detection, prior to the initiation of this thesis.
Single-molecule detection describes analytical techniques that are able to identify
the presence of an individual molecule, and most typically, fluorescent molecules. Singlemolecule techniques can be achieved by a variety of optical configurations, and all of
these require efficient elimination of background fluorescence [30]. These optical
techniques include narrow-field epifluorescence[31], fluorescence correlation and crosscorrelation spectroscopy[32] via laser confocal microscopy[33],

and various other

methods that restrict the fluorescence excitation volume[34, 35]. By one method, total
internal reflection fluorescence (TIRF) microscopy, the excitation volume is confined to a
one-hundred nanometer section of the specimen, enabling high signal-to-noise for
molecules located on the imaging surface (Figure 4) [36, 37].
Single-molecule detection holds great potential for biomarker analysis since with
it comes the ability quantify molecules with digital resolution, i.e. by counting each
molecule. Single-molecule detection and quantification has proven to be a boon in the
DNA sequencing world. Since the development of Polony (polymerase colony)
technology[38], which isolates individual molecules and performs separate sequencing
reactions in parallel, next-generation sequencing technologies have exploded[39]. (Until
2009, the number of sequenced human genomes was less than ten. By the end of 2010
that number was approximately 3,000. By the end of 2011, that number is estimated to be
approximately 30,000[40].) The single-molecule nature of these technologies has been
proven to be more quantitative, accurate, and precise than previous analog methods like
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the microarray[41, 42]. One of the reasons for this is that dynamic range becomes
trivialized to the task of sampling more molecules (e.g. by expanding the imaging area).
Theoretically speaking, to sample an event present at a one-in-a-million, one needs only
to image around one million molecules at single molecule resolution – a task attainable
on 1 cm2 of surface. Despite this potential, a deep survey of the literature at the outset of
this thesis and until 2009 shows that no single-molecule method had been published that
examines immunoassay protein detection on a solid surface (Figure 5).
With a strong impetus that single-molecule detection could greatly benefit the
world of protein detection, I embarked on this thesis to develop single-molecule tools for
protein diagnostics and proteomics. The aim of Chapter Two of this thesis is to develop a
single-molecule immunoassay on a solid surface, and in the process, uncover the
technological barriers that exist to single-molecule diagnostics. Throughout the course of
that aim I discovered that low-background surface chemistry was one of the major
barriers to the adoption of single-molecule methods into protein detection. This paved the
way for Chapter Three, in which I examine a recently published biomaterial called
poly(ethylene glycol)-bovine serum albumin (PEG-BSA) nanogels[43] and study its use
in single-molecule detection applications. Initially directed as a study to characterize the
nanogels for protein diagnostic applications, I was satisfied to find the nanogel
biomaterial to have benefits to general biophysical studies involving single-molecule
imaging. Having established the principle techniques in single-molecule imaging, surface
chemistry, and surface architecture, I sought to fully integrate single-molecule detection
into the immunoassay toolkit. I chose the antibody microarray as the technology that can
most readily benefit from single-molecule detection, and in Chapter Four, I provide a
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proof-of-principle for the use of single-molecule imaging and nanogel surface chemistry
in the antibody microarray arena. Finally, in Chapter Five, I introduce a novel proteomics
technology that relies neither on mass spectrometry nor on a large collection of
antibodies. With this technology, a small number of antibodies (8 to 50) could be used to
obtain sequence information from denatured proteins or peptides in a massively parallel
fashion. These antibodies, which detect peptide sequence information, may be bound and
washed away in sequence with one another and detected by single-molecule imaging to
identify and quantify the collection of over 23,000 human proteins in a single experiment.
In addition to introducing the method and its two variations, I provide computational and
experimental data that support the development of the technology.
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Figure 1

Cancer survival rates from adenocarcinomas with early and late detection[11]
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Figure 2

The relative contribution of proteins within plasma[16]
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Figure 3

Dynamic range of plasma proteins spans ten orders of magnitude.[17]
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Figure 4

Total internal reflection fluorescence (TIRF) microscopy[44]
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A deep literature search of the single-molecule fluorescence literature in 2009

Figure 5
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CHAPTER TWO: PROTEIN QUANTIFICATION IN
COMPLEX MIXTURES BY SOLID PHASE SINGLEMOLECULE COUNTING
This chapter embodies a manuscript that was published in the journal Analytical
Chemistry on July 14, 2009. This chapter describes a novel method that Robi D. Mitra
and I developed for quantifying proteins on a solid surface using an immunoassay that
has single-molecule sensitivity. In this chapter, I overcome the obstacles that prevented
the use of single-molecule imaging in an immunoassay and demonstrate the utility of the
method in research and clinical applications. This study was conducted under a sponsored
research agreement with Helicos Biosciences, Inc. Jeffrey Reifenberger trained me in
Cambridge, MA to use and set up a total internal reflection fluorescence (TIRF)
microscope. The experiments in this study were designed by Robi D. Mitra and me, and
the experiments, software development, and TIRF setup were performed by me.
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ABSTRACT
Here we present a procedure for quantifying single protein molecules affixed to a
surface by counting bound antibodies. We systematically investigate many of the
parameters that have prevented the robust single-molecule detection of surfaceimmobilized proteins. We find that a chemically adsorbed bovine serum albumin surface
facilitates the efficient detection of single target molecules with fluorescent antibodies,
and we show that these antibodies bind for lengths of time sufficient for imaging billions
of individual protein molecules. This surface displays a low level of nonspecific protein
adsorption, so that bound antibodies can be directly counted without employing two-color
coincidence detection. We accurately quantify protein abundance by counting bound
antibody molecules and perform this robustly in real-world serum samples. The number
of antibody molecules we quantify relates linearly to the number of immobilized protein
molecules (R2 = 0.98), and our precision (1-5% CV) facilitates the reliable detection of
small changes in abundance (7%). Thus, our procedure allows for single, surfaceimmobilized protein molecules to be detected with high sensitivity and accurately
quantified by counting bound antibody molecules. Promisingly, we can probe flow cells
multiple times with antibodies, suggesting that in the future it should be possible to
perform multiplexed single-molecule immunoassays.

INTRODUCTION
Our ability to detect and quantify proteins has lagged behind our ability to analyze
nucleic acids. Closing this gap by developing more sensitive and quantitative protein
analysis methods would greatly aid efforts to understand cellular processes[45, 46] and to
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search for protein biomarkers that reveal disease state.[15, 47] The application of singlemolecule detection (SMD) methods to proteins holds great promise in this regard for five
reasons: 1) Recent advances have made SMD methods inexpensive, robust, and
reliable.[48, 49] 2) SMD methods can enable the detection of low-abundance
proteins[50-52], which is especially important because the poor sensitivities of current
proteomic methods are limiting progress in the area of biomarker discovery.[53, 54] 3)
SMD methods can enable protein quantification by employing single-molecule counting,
which can be significantly more accurate than bulk methods.[41, 42] 4) SMD methods
can enable analysis of protein-protein interactions by detecting single-molecule colocalization.[55] 5) SMD methods for proteins affixed to a surface could enable highly
multiplexed immunoassays. For example, by creating ~ 20 overlapping pools of labeled
antibodies using a logarithmic pooling strategy like the one used to decode bead-based
random microarrays[56], a single assay could detect the protein targets of all 6,000 nonredundant human proteome antibodies[57] with only ~ 20 binding rounds.
There are several obstacles that have hampered the development of singlemolecule immunoassays. One is the lack of a good surface for the SMD of surfaceimmobilized proteins. An ideal surface would be resistant to nonspecific antibody
adsorption, while still allowing for the specific binding of antibodies to their target
molecules. Efforts have been made to develop better surfaces[43, 58-68], however, the
nonspecific adsorption on these surfaces has not been characterized with single-molecule
resolution, with a few exceptions.[59, 60] To work around high background surfaces,
researchers have introduced innovative detection schemes, often relying on two-color
coincidence detection.[69, 70] This helps to reduce detection noise but is suboptimal for a
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proteomic method, since 1) pairs of protein-specific capture reagents with nonoverlapping epitopes may not be obtainable for all proteins, 2) generating pairs of
reagents increases cost, and 3) determining the optimal binding conditions for dual
antibody sandwich immunoassays can require more optimization than for single-capture
antibody immunoassays.[71] A second obstacle to single-molecule immunoassays is the
dissociation of antibodies from their individual targets during imaging. Many antibodies
rapidly dissociate from their ligands in solution, but surface dissociation is often slower.
It is not known whether the surface dissociation rates of antibodies will enable the
sensitive detection of single ligand molecules. Finally, a single-molecule immunoassay
must be able to sample large number of molecules in each experiment to ensure accurate
protein quantification and to maximize the dynamic range.
Here we demonstrate a method for quantifying protein molecules on a surface by
counting bound antibodies. To achieve this, we first optimized an image acquisition and
processing method for SMD of fluorescently labeled antibodies on the surface of a flow
cell. Then we systematically evaluated 12 surface chemistries for single-protein
detection. For each surface, we quantified the nonspecific adsorption of single antibody
molecules and characterized the efficiency of target protein immobilization. We found
that a chemically adsorbed bovine serum albumin (BSA) surface had the lowest
nonspecific binding and still allowed for efficient protein sample attachment. Using this
surface incorporated into a flow cell, we measured the fraction of immobilized proteins
that could be detected by direct antibody binding, and found that a high fraction of targets
(at least 70%) were bound specifically. We directly measured the surface dissociation of
antibodies from their ligands and found it to be highly suited for large scale single-
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molecule quantification. We further showed that proteins were accessible to antibody
binding over multiple binding rounds. Finally, we were able to quantify immobilized
proteins by directly counting bound antibody molecules. A sufficiently low level of
background binding was observed such that single target molecules could be detected
without employing two-color coincidence detection. We found this method was both
accurate and sensitive – the number of antibody molecules counted was linearly related to
the number of proteins (R2 = 0.98), and as few as 55 ligand molecules per 1,000 µm2
image (1.4 pg cm-2) could be detected over background. Our detection method showed
robustness in the background of a complex biological fluid, and we demonstrated the
accurate quantification of an endogenous protein within blood serum samples. Thus, we
have resolved many of the issues that have limited the feasibility of solid phase singlemolecule protein analysis and have demonstrated reliable protein quantification in
biological samples by single molecule counting on a solid surface.

RESULTS AND DISCUSSION
There are a number of formats and methods by which the SMD of biomolecules
can be achieved.[30] We chose total internal reflection fluorescence (TIRF) microscopy
as the basis for our single-molecule immunoassays. We attach a small amount of protein
sample to the surface of a flow cell, probe with fluorescent antibodies, remove unbound
antibodies and directly image the bound antibodies (Figure 6A).
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Iterative Thresholding Improves Detection of Labeled Antibody Molecules
We first sought to verify that our detection system could achieve single-molecule
resolution of fluorescent antibody molecules affixed to glass. We mixed Cy3-labeled
antibodies with identical antibodies labeled with Cy5, diluted the mixture, and reacted it
to an epoxide-coated glass slide. We performed TIRF imaging with Cy3 and Cy5
channels, determined the positions of the Cy3 and Cy5 antibodies using software, and
overlaid the positions (Figure S1). The Cy3-labeled molecules did not co-localize with
Cy5-labeled molecules more than would be expected by chance (p = 0.78, Fisher’s Exact
Test), demonstrating that the fluorescence objects detected were not clusters of antibodies
(which would have been detected as co-localized molecules) but single antibody
molecules.
In these initial experiments, we observed considerably fewer fluorescent
antibodies at the edges of our field of view relative to the center of the image. This is due
to the non-uniform laser illumination intrinsic to our Nikon optical design (Figure 6B).
Since this non-uniform illumination greatly reduces the number of antibody molecules
that can be analyzed in a single field of view using standard, single value thresholding,
we developed an automated and unbiased image processing technique, “iterative
thresholding” (see Supporting Methods). The algorithm uses local thresholds to
compensate for the lower intensities at the edges and is able to accurately identify the
locations of fluorescent antibodies independent of their position within the field of view.
We tested the performance of this technique by comparing images processed with our
iterative thresholding algorithm with the same images analyzed by single value
thresholding. Our iterative thresholding algorithm (Figure 6D) identified the positions of
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14-fold more antibodies per field of view (1,408% ± 420%), on average, than the
standard method (Figure 6C) while introducing few false positives with respect to the raw
data (sensitivity = 99.96% ± 0.07%, specificity = 98.47% ± 0.76%). Thus iterative
thresholding substantially increased the efficiency of fluorescent antibody analysis using
objective TIRF and provided a foundation for our protein quantification method.

Study of Surface Nonspecific Adsorption
Minimizing the nonspecific adsorption of antibodies to surfaces is critical for the
development of single-molecule immunoassays because it causes false positive events,
decreasing the accuracy and sensitivity of the assays. To find the best surface for singlemolecule immunoassays, we systematically searched the literature to identify surfaces
that were shown to have minimal interactions with antibodies. We chose surface
chemistries previously used for SMD[60] and for biosensors[58, 62, 63, 66], as well as
several that we speculated would exhibit low levels of non-specific protein adsorption.
Some protocols were followed directly from the literature while others, such as the
chemically adsorbed BSA protocols, were modified (see Materials and Methods).
We quantified the nonspecific adsorption of antibodies for 12 different surface
chemistries. We loaded a glass slide into a flow cell, treated it according to a particular
surface protocol, exposed it to Cy5-labeled antibody, washed away unbound antibodies,
and quantified the number of adsorbed antibody molecules by single-molecule counting
(Figure 6E). Since no ligand was present on the surface of the slide, each surface-bound
antibody represented a nonspecific adsorption event. We observed 122 to 2,600
antibodies per 1,000 µm2, (3 to 68 pg cm-2). We found that a chemically adsorbed BSA
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surface (first developed by Heyes et al[60] and modified here to allow adsorption to the
glass via epoxide crosslinking and capping) showed the least amount of nonspecific
binding. Dextran, aminodextran, and the smaller molecular weight linear polyacrylamide
(LPA) surfaces showed moderate adsorption. Among these three protocols, polymers of
lower molecular weight (1,500 and 5,000 g/mol) performed better than those of higher
molecular weight (10,000 and 500,000g/mol). Large LPA, CM-dextran, glucose, IgG,
amino-PEG and PEG performed the worst.
These finding were consistent with those reported by Heyes et al[60], who found
that chemical immobilization of BSA onto a glass surface provided great reduction in
nonspecific adsorption of streptavidin molecules. By atomic force microscopy, they
showed that this surface was highly homogeneous, supporting the hypothesis that the 75
kDa BSA protein creates a neutral, hydrophilic layer that sterically hinders proteins from
nonspecifically adsorbing to the sticky silicon dioxide below. Based on the performance
of our adapted BSA surface, we selected the chemically adsorbed BSA surface for further
characterization.

Robust Immobilization of Protein Ligands on BSA-Coated Glass
It is important that a single-molecule immunoassay surface allows for the robust
anchoring of ligand molecules. However, it was not clear whether the low background
BSA surface discussed above could provide enough functional groups for the attachment
of a protein sample. Therefore, we tested how efficiently proteins would anchor to the
BSA

surface

using

the

heterobifunctional

crosslinking

system

1-ethyl-3-(3-

dimethylaminopropyl)carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide
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(NHS). We prepared a BSA surface in a flow cell and activated the free carboxyl groups
on the BSA molecules with EDC and NHS. We washed the flow cell to remove unbound
crosslinker and then exposed the flow cell to Cy3-labeled protein to immobilize the
proteins via their primary amines. The flow cell was washed again to remove unbound
protein molecules, un-reacted crosslinking sites were quenched, and the flow cell was
imaged.
Crosslinking proteins to the BSA surface allowed for a ten-fold increase in the
number of protein molecules affixed to the surface compared to the surface without
EDC/NHS activation (950% ± 52%). Also, the proteins were able to be attached at over
1,000 molecules per field of view – a density that allows for high-throughput singlemolecule sampling (Figure S2). Thus, we concluded that the EDC/NHS system was able
to effectively activate the BSA surface and attach a protein sample. The chemically
adsorbed BSA surface with EDC/NHS sample immobilization provided the surface
chemistry for all subsequent experiments (Figure 6A).
We enable protein sample attachment by generating peptide bonds between the
solvent-accessible carboxyl groups of the BSA and the primary amine groups of the
target proteins. This contrasts the approach of some single-molecule studies which have
relied on biotin streptavidin linkage.[60, 72] Our method does not rely on pre-labeling
samples by biotinylation, instead taking advantage of endogenous lysine residues present
on most proteins. Therefore our approach may provide a more universal way of attaching
heterogeneous biological samples.
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Efficient Detection of Single Protein Molecules by Antibody Binding
The accuracy of a single-molecule immunoassay depends on the accessibility of
target molecules to antibodies; inaccessible ligands will not be detected or counted. There
are several mechanisms that can prevent an antibody from binding a ligand immobilized
on a solid substrate. Steric, electrodynamic, and thermodynamic variables can hinder
binding when repulsive forces of the surface overcome the attractive forces of the
antibody-protein complex. Kinetics can also hinder binding if a free energy barrier is
sufficiently high to prevent docking on relevant time scales.[73] We sought to determine
to what degree these variables affect the accessibility of target molecules to antibodies in
our system.
To analyze the binding of target molecules by antibodies, we performed a dualcolor, single-molecule protein accessibility assay (Figure 7). Here, the target proteins
were labeled with Cy3 and the antibodies were labeled with Cy5. We prepared a BSA
surface within a flow cell, immobilized the target proteins, capped the reactive
crosslinking sites, and acquired a pre-antibody image. Then, we probed with antibodies,
washed away unbound antibodies, and imaged. We compared the positions of the
antibodies with the positions of the proteins imaged beforehand by overlaying their
locations. To verify that the co-localization of proteins and antibodies was a result of
specific binding, we measured the correlation between protein and antibody positions and
tested that correlation for randomness (see Supporting Methods). The correlogram in
Figure 7 indicates that antibody binding was specific and not due to chance correlation.
(To confirm the specificity of binding we also performed the protein accessibility assay
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using a nonspecific target protein with which the antibodies should have had no affinity
and observed a correlogram showing no significant correlations (Figure S3).)
To quantify ligand accessibility, we measured the fraction of proteins that were
co-localized with antibodies. We then performed this protein accessibility assay for
different antibody concentrations. The total fraction of proteins bound by antibodies is
shown by the dashed line in Figure 8. To better determine the amount of specific binding,
we estimated nonspecific binding based on the observed antibody density and subtracted
that from the total binding (see Supporting Methods). The dotted line shows the estimated
fraction of proteins that overlapped with antibodies as a result of nonspecific binding,
while the solid line shows the fraction of specifically bound ligand molecules.
The accessibility curve follows the behavior of fractional occupancy that is
expected from binding theory. When 1 µg/ml antibody is used, ~ 70% of the target
molecules were specifically bound by antibodies. From these results, we conclude that
single protein molecules can be efficiently detected by counting bound antibody
molecules.

Surface Dissociation of Antibodies
We sought next to determine if the ligand molecules that we failed to detect in the
protein accessibility experiments described above were not detected because they were
never bound by antibodies, or if they were initially bound by antibodies but the
complexes dissociated before imaging. Antibody-ligand interactions are known to have
dissociation half-lives in solution ranging from minutes to several hours. However, the
surface dissociation rate may be slower due to surface-antibody interactions that stabilize
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the complex. Therefore, we designed an experiment to measure the surface dissociation
rate of antibodies bound to single ligand molecules.
To measure the surface dissociation rate of the antibodies, we allowed antibodies
to bind to target proteins that were immobilized on the surface of the flow cell, as
previously described. We imaged the surface to determine the starting number of
antibody:ligand complexes and then began a continual wash to remove unbound
antibodies from the flow cell. We imaged the surface every 8 hours over a 48 hour
period. At each time-point we quantified the number of antibody:ligand complexes that
were lost relative to the starting time point, and from this we measured the surface
dissociation of the antibodies.
Nearly all (> 90%) of the co-localized pairs of proteins and antibodies remained
intact for 48 hours at room temperature (Figure S4). Furthermore, antibody dissociation
did not follow exponential decay over this time period. Together, these results suggest a
strong antibody-surface interaction. The high stability of bound antibodies also explains
how we were able to detect single ligand molecules with high efficiency (i.e. Figure 8)
even though we thoroughly washed the flow cell.
The half life of a typical antibody:ligand complex can be as short as several
minutes in solution. Such rapid dissociation would pose a serious barrier to the
development of a solid phase, single-molecule immunoassay because antibodies would
be washed off of the surface of the flow cell before they could be detected. Fortunately,
surface interactions appear to stabilize antibody:ligand interactions.

Using

the

observed surface dissociation rate we calculated the dynamic range that can theoretically
be achieved. If ligand molecules are immobilized at a density of 1,000 target molecules
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per image and 10 images are acquired per second (a rate possible with the current
generation of charge-coupled device cameras), then one can acquire images of
1,000*0.9*10*60*60*48 = 1.5 billion target molecules while retaining 90% of the
antibodies on the surface. Thus, the observed surface dissociation rate will support a
dynamic range of 9 orders of magnitude. This suggests that it should be possible to
develop single-molecule immunoassays with a high dynamic range.

Dual-round protein binding
Ligand rebinding in successive binding rounds could be used to increase detection
specificity or to enable efficient sample multiplexing.[56] However, as our surface
dissociation experiments illustrated, it was difficult to remove bound antibodies from the
surface. This was true even after washing with various antibody eluting reagents (data not
shown). Therefore, we wanted to explore rebinding ligands by “erasing” antibodies from
the surface via photobleaching. We believed rebinding after photobleaching might be
possible because the antibodies we used was polyclonal and could theoretically bind
multiple epitopes on a single ligand.
One hurdle to performing multiple binding rounds with an intermediate
photobleaching step is that the antibodies that bind in the first round could competitively
inhibit the binding of antibodies in subsequent rounds. To test whether competitive
binding would be a major phenomenon, we probed Cy3-labeled ligand molecules with
Cy5-labeled antibodies as described above and acquired the positions of the bound
antibodies. We then photobleached the antibodies with 640nm light before performing a
second round of binding with the same antibody. (Target molecules were not bleached.)
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If antibodies competitively inhibited the second round of binding, then we should not
have observed any ligand molecules that were bound in both rounds.
We observed 2,829 Cy3-labeled ligand molecules. Of these, 1,497 proteins were
bound in round 1, 1,146 were bound in round 2, and 526 (18.6%) were bound twice.
Assuming independent binding in round 1 and round 2, we would expect 21% of the
ligands to be bound bind twice. Thus, approximately 87% of the proteins bound in round
1 were available for binding in round 2 (Figure 9). This result supports the feasibility of
performing multiple rounds of single-molecule protein detection.

Quantification of Single Molecules by Antibody Binding
We next set out to perform a quantitative immunoassay, counting single,
immobilized protein molecules by detecting bound antibodies. We affixed varying
amounts of Cy3-labeled protein onto the surface and quantified the number of
immobilized target molecules by imaging. Then we probed the surface with Cy5-labeled
antibodies and counted the total number of bound antibodies after washing.
The solid line in Figure 10 illustrates the relationship between number of antibody
molecules and number of protein molecules affixed to the surface. In the range of 55 to
1,676 target molecules per 1,000 µm2 image, we observed a linear relationship between
the number target molecules and antibodies. The lower limit of detection (LOD) of 55
molecules per 1,000 µm2 image (1.4 pg cm-2), was achieved by acquiring only 5 images.
It should be possible to detect lower quantities of surface-bound proteins by acquiring
greater numbers of images.[51] Given our sample immobilization efficiency and this
LOD, we were able to detect proteins in solution down to 100 pM. In this proof-of-
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principle study, we did not attempt to maximize the attachment efficiency, but doing so
should increase the detection sensitivity.[51]
The standard curve displays high correlation (R2 = 0.98), and we obtain precision
between 1% and 5% CV. By acquiring only 5 images we can robustly detect abundance
changes down to 7% – we generated 99% confidence intervals around each data point,
and the widest interval was a 7% deviation. This result demonstrates the utility of digital
quantification.
We also quantified the Cy3-labeled target protein in the presence of serum. Here,
we spiked Cy3-labeled target protein at varying concentrations into neat rabbit serum.
The complex mixture, including target and non-target proteins, was immobilized to the
BSA surface. We probed with fluorescently-labeled antibody and quantified the number
of target proteins versus the number of antibodies on the surface.
Similar results to the purified protein detection curve were obtained,
demonstrating the robustness of the method in the presence of a complex biological fluid
(Figure 10, dashed line). The LOD in serum was 390 molecules per 1,000 µm2 (10 pg cm2

) corresponding to a target starting concentration of 1 µg/ml. By comparison, the total

concentration of the serum was 74 mg/ml (by dry weight). Therefore, despite the
overabundance of serum proteins, the serum introduced almost no background. This
indicates that single-antibody, direct binding can be used to make specific detection
measurements in a highly complex biological fluid.
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Accurate Quantification of an Endogenous Serum Protein
We next applied our method to quantify endogenous protein in a biological
sample. We quantified the amount of total IgG in blood of a rabbit at various time points
after immunization. Serum samples were diluted in PBS, immobilized to flow cell
surfaces, and probed with anti-rabbit IgG Cy5-antibody. Then we quantified the
antibodies remaining on the flow cell surface after washing.
We detected a 70.0% increase (± 8.1%) in total IgG between pre-immunization
and week 4, as well as a subtle 11.7% increase (± 4.4%) between weeks 4 and 5 (Figure
11). Our single-molecule quantitation measurements matched bulk measurements
obtained by ELISA, deviating from the gold-standard by at most 4.2% (see Supporting
Methods). This demonstrates the accuracy of single-molecule quantitation in complex,
real-world samples.

CONCLUSION
Recent advances in SMD have the potential to usher in a new generation of
proteomics tools. Toward the goal of uniting the field of protein detection with singlemolecule counting, we present a proof-of-principle in which we quantify the abundance
of individual proteins on a solid surface by counting bound antibodies. Further, we
demonstrate quantitation of an endogenous protein in real-world serum samples while
eliminating the need for two-color coincidence detection. We optimized key parameters –
image

acquisition

and

processing,

nonspecific

antibody

adsorption,

sample

immobilization, sample accessibility, and surface dissociation – in a systematic way to
enable a quantitative immunoassay. Because these parameters are interconnected, we
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found that it was important to optimize them simultaneously, which allowed us to
quantify small changes (7%) in abundance of target proteins by single-molecule counting.
An important future goal is to perform multiple rounds of antibody binding on a
solid surface to allow for efficient multiplexing.[56] This would be achieved by encoding
each binding pool with a predetermined mixture of antibodies, so that n protein targets
could be quantified in ~ log2n binding rounds (Figure S5). The ability to perform multiple
rounds of binding would also enable error-checking, since antibodies would get a second
pass at detecting a particular target. Additionally, analysis of protein-protein interactions
would follow easily from such an approach, since interacting proteins will be present at
the same positions on the flow cell.
Towards this goal, we have demonstrated the serial detection of proteins by two
rounds of antibody binding. We used a photobleaching step after the first round of
binding to erase surface-associated fluorescence prior to the second hybridization. We
used photobleaching because the rate at which specifically bound antibodies dissociated
from the surface was low enough that we found it difficult to completely remove them
from the flow cell in a reasonable amount of time. Using this approach, we found that the
majority (87%), of proteins that we expected to be bound in two binding rounds were in
fact bound twice, indicating that competitive binding by the bleached, surface-bound
antibodies was minimal. This lends support to the feasibility of multiple rounds of
antibody binding and detection, with each round separated by a photobleaching step.
(Alternatively, one could use a cleavable linker between the antibody and fluorophore,
which would enable dye removal by exposure to a reducing agent or to light.[74])
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Washing with surfactants and denaturants may allow us to better remove bound
antibodies from their targets. For example, recent work demonstrated the efficient
stripping of antibodies from western blots without disrupting protein attachment.[75] To
develop such a protocol in a single-molecule setting will require a low-background
surface that is also surfactant-compatible (the surfaces described here are not). We are
now investigating low-background surfactant-compatible surfaces that utilize multi-arm
PEG microgels.[76]
Some obstacles still must be overcome before it is feasible to develop a
multiplexed single-molecule immunoassay. For example, since each antibody-ligand pair
has variable affinities, they each may need to be characterized beforehand in order to
ensure that the concentration of antibody used in the immunoassay is high enough to
ensure maximal binding to its immobilized ligand. However, as antibody production and
characterization becomes more standardized, it will become possible to obtain large
numbers of well-characterized antibodies. For example, the Human Antibody Initiative
has already generated and curated antibodies against over 6,000 human proteins, and they
aim to expand the collection to the entire human proteome within the decade.[57] Solid
phase single-molecule immunoassays could provide a way to leverage such antibody
collections toward high-throughput proteomic applications.

MATERIALS AND METHODS
Imaging
All experiments were performed on a Nikon TE-2000 inverted microscope fitted
with a total internal reflection fluorescence (TIRF) illuminator (Nikon, Melville, NY).
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Two lasers, 532 nm/75 mW and 640 nm/40 mW were used for fluorescence excitation
(Compass 215M, Cube-40C, Coherent, Santa Clara, CA). Illumination of the sample was
controlled through a computer animated shutter (Prior Scientific, Rockland, MA). The
532 nm laser beam was attenuated by a ND 2 neutral density filter (Nikon, Melville, NY).
The two beams were coupled into one end of an optical fiber cable using a dichroic
mirror (Z532BCM, Chroma, Brattleboro, VT), with the other end of the cable attached to
the TIRF illuminator. Before reaching the objective, each laser beam passed through a
band pass filter: HQ545/30 for the green laser and D635/30 for the red laser (Chroma,
Brattleboro, VT). Objective type total internal reflection was achieved through a 60x
TIRF oil objective with index of refraction 1.49 (Nikon, Melville, NY). The chemistry of
the assay was performed in a flow cell (see Fluidics) mounted onto the microscope stage.
When the lasers are experiencing TIR, an evanescent wave decays exponentially at the
glass-water interface into the flow cell to a distance of about 300 nm. TIRF allows for the
excitation of only surface-bound fluorophore-labeled antibodies and therefore reduces the
overall fluorescence background. The emitted photons from the labeled antibodies were
collected by the objective and passed through a dichroic mirror (custom Cy3/Cy5,
Semrock, Rochester, NY) and an emission filter for either the green channel (HQ610/75,
Chroma, Brattleboro, VT) or the red channel (LP02-647RU-25, Semrock, Rochester,
NY). Light was then detected by a charge coupled device (CoolSnap ED, Roper
Scientific, Tucson, AZ) which imaged a 140 µm by 100 µm (1,400 px x 1,000 px) region
of the surface.
Immediately prior to image acquisition, the flow cell was washed with 600 µl
PBS and loaded with 600 µl oxygen scavenger and blink-reduction system[77] to prevent
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dyes from photobleaching and blinking. Then images were acquired in the red and green
fluorescence channels at five different positions across length of the flow cell, with 0.5
second exposure. Custom software written in Metamorph (Molecular Devices,
Sunnyvale, CA) and Matlab (Mathworks, Natick, MA) was used to analyze the locations
and intensities of the fluorescent molecules (see Supporting Methods).

Fluidics
The analysis substrate was a 40mm diameter, #1.5 glass slide (Erie Scientific,
Waltham, MA). The substrate was epoxide-derivatized by the vendor unless otherwise
specified in Surface Preparations. The slide was loaded into a flow cell (FSC2, Bioptechs,
Butler, PA) fitted with perfusion ports to allow for reagents to be passed over the surface.
Reagents were flowed through by a custom-made negative pressure vacuum pump.

Target Proteins
The target proteins were polyclonal goat IgG molecules labeled with an average
of 8 Cy3 dyes per molecule. The nonspecific target proteins used as a negative control in
the target binding accessibility assay were polyclonal rabbit IgG molecules labeled with
Cy3. Proteins were obtained from Abcam (Cambridge, MA).

Serum Samples
The serum sample used for the spike-in quantification experiment was obtained
from rabbit. The serum samples used for the endogenous protein quantification
experiment were from pre-immunized, week 4, and week 5 rabbits in an antibody
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production protocol (for an unrelated study) during which rabbits were immunized with
antigen and adjuvant. All serum samples were obtained from 21st Century Biochemicals
(Marlboro, MA).

Antibodies
The antibodies used in all experiments with the exception of the endogenous
protein quantification experiment were polyclonal anti-goat, labeled with Cy5. The
antibodies used to detect endogenous rabbit IgG were polyclonal anti-rabbit, labeled with
Cy5. All antibodies were obtained from Abcam (Cambridge, MA).

Preparation of Surfaces
Twelve surfaces were generated by protocols taken directly from or adapted from
surface blocking protocols in the literature.[43, 59-68] Nine of the surface chemistries
were generated by the chemical attachment of primary amine groups of a polymer or
small molecule to epoxide-derivatized glass. The epoxide-coated glass was loaded into
the flow cell and washed in 600 µL phosphate buffered saline pH 7.3 (PBS). The glass
was reacted with one of the following solutions in PBS, for 1 hr at room temperature: 1%
bovine serum albumin (BSA) (Fisher Scientific, Pittsburg, PA), 1% BSA / 0.1% cold
water fish skin gelatin (Aurion, Netherlands), 1M glucose, 10% linear polyacrylamide
(LPA) MW 1500 Da, 10% LPA MW 10 kDa, 10% LPA MW 1 MDa, 100 mg/ml aminoPEG (Sigma-Aldrich, St. Louis, MO), 200 µg/ml rabbit IgG (Abcam, Cambridge, MA),
and 100 mg/ml aminodextran MW 500 kDa (CarboMer, San Diego, CA). These surfaces
were then capped with 1 M Tris pH 8.0 for 20 minutes. Two of the surfaces were
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generated by the noncovalent adsorption of a polymer to the glass. Here the epoxidecoated glass was first capped with ethanolamine-HCl pH 8.0 for 20 minutes and then
treated with one of the following solutions in PBS for 1 hr at room temperature: 100
mg/ml dextran and 1% PEG MW 5 kDa (Sigma-Aldrich, St. Louis, MO). The
carboxymethyl (CM) dextran surface was generated as previously described.[62]

Measuring Nonspecific Adsorption
A flow cell containing the surface to be tested was loaded with 600 µl, 100 ng/ml
Cy5 antibody. The surface was exposed to the antibody in the dark for 25 minutes at
room temperature. Then, unbound antibodies were removed with a 600 µl PBS wash, and
the flow cell was imaged as described above.

Immobilizing Protein Samples
A chemically adsorbed BSA surface was formed as described above, and the
surface was activated with 0.2 M 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
hydrochloride (EDC) and 0.05 M N-hydroxysuccinimide (NHS) (Pierce, Rockford, IL) in
sodium phosphate buffer pH 5.8 (SPB) for 10 minutes. Free EDC and NHS was washed
away with 600 µl SPB.
The attachment of the protein sample of interest to the activated surface was as
follows. For immobilization of purified target protein, 100 ng/ml (unless otherwise
specified) of target protein in PBS was loaded into the flow cell. To generate a standard
curve of detection, dilutions of target protein in PBS were loaded into the flow cell. To
generate a standard curve of detection for target protein in the presence of serum,
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dilutions of target protein were spiked-in to whole rabbit serum, and the spiked-in serum
was loaded into the flow cell. To detect endogenous IgG in serum, whole rabbit serum
was diluted 1:105 in PBS and loaded into the flow cell.
Proteins samples that were loaded into the flow cell were allowed to react with the
surface for 10 minutes at room temperature, in the dark. Then, unbound proteins were
removed with a 600 µl PBS wash, and unreacted EDC-NHS sites on the BSA surface
were quenched with 1M Tris pH 8.0 for 20 minutes.

Antibody Binding and Oxygen Scavenging
After a protein sample was immobilized onto the flow cell surface (as described
above), the Cy5-labeled antibody was loaded into the flow cell at 100 ng/ml (unless
otherwise noted) in PBS and incubated for 2 hrs in the dark at room temperature.
Unbound antibodies were washed away, and the flow cell was imaged.
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FIGURES
Figure 6

(A) Illustration of the single-molecule immunoassay. A chemically adsorbed BSA
surface was prepared by reacting BSA with an epoxide-coated glass slide within a flow
cell. Unreacted epoxides were quenched and the BSA was activated for sample
immobilization by EDC/NHS. The protein sample (circles) was immobilized to the BSA
surface, and unreacted sites were passivated. The flow cell was probed with fluorescently
labeled antibody and imaged. (B) The raw TIRF image of Cy5-labeled antibodies (scale
bar = 50 µm) illustrates the nonuniform TIRF illumination. (C) Image processing by
standard, single value thresholding allowed only a small portion of the raw image (the
brightest spots) to be used for molecule identification. (D) Image processing by iterative
thresholding allowed for most of the raw image (regardless of intensity) to be used to
molecule identification. (E) Nonspecific adsorption of antibodies onto twelve surface
protocols. Molecules were counted in 5 x 1,000 µm2 images, and units were converted to
picograms per cm2 assuming a 155kDa molecular weight. The chemically adsorbed BSA
surfaces suppressed nonspecific adsorption the most.
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Figure 7

Determination of protein accessibility (detection efficiency). The image series illustrates
target immobilization, antibody binding, and correlation detection. Each frame is an
image of the same position in the flow cell (scale bar = 2 µm) and shows ~ 21 of the ~
103 targets analyzed in each binding experiment. (i) After target protein immobilization,
images of the Cy3-labeled proteins were acquired (top), and the positions of the proteins
were determined by software (bottom). (ii) The surface was probed with antibody, images
of bound Cy5-labeled antibodies were acquired (top), and positions of the antibodies
were determined by software (bottom). (iii) Positions of the targets (green) and antibodies
(red) were overlayed. Yellow pixels represent the co-localized molecules, indicating
antibody-bound proteins. (iv) The correlogram analysis of this flow cell indicated that
protein and antibody co-localization was nonrandom (i.e. antibodies were specifically
binding to targets).
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Figure 8

Protein accessibility (detection efficiency) as a function of antibody concentration.
Specific binding (solid) was calculated by subtracting the nonspecific binding (dotted)
from total binding (dashed). We could specifically bind as much as ~ 70% of the target
molecules, enabling efficient protein detection.
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Figure 9

Protein rebinding. The image series illustrates two binding rounds separated by a
photobleaching step (scale bar = 2 µm). Top: Raw images of Cy3 (green) and Cy5 (red)
channels. Yellow represents merged channels. Bottom: Analyzed positions of protein
molecules (green), antibody molecules (red) and co-localized antibody:protein molecules
(yellow). Circles indicate proteins that were bound in both rounds. (i) First round of
antibody binding detects immobilized proteins. (ii) Antibodies are photobleached. (iii)
Second round of antibody binding detects many of the same proteins. We found that our
surface allows for two successful rounds of binding.
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Figure 10

Single-molecule protein quantification. Solid line: We demonstrate a linear relationship
between the number of antibody molecules and the number of protein molecules on the
surface when detecting a purified protein sample. Linear fit R2 = 0.988; coefficient of
variation = 1 - 7%; lower limit of detection 55 molecules per 1,000 µm2 image (1.4 pg
cm-2). Dashed line: We achieve accurate quantification in a complex protein sample.
Detection of target protein spiked into undiluted rabbit serum produces a quantification
curve that deviates only slightly from quantification of the purified sample. We did not
observe any increase in background when detecting in serum.
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Figure 11

Quantification of endogenous

IgG in

serum.

Using single-molecule protein

quantification, we accurately measured the total IgG levels of a rabbit at various time
points after immunization. Top: Single molecule counting at three time points (scale bar
= 5 µm). We detected a 70.0% increase (± 8.1%) in IgG levels between pre-immunization
and week 4, and a 11.7% increase (± 4.4%) between weeks 4 and 5. Bottom: Bar graph
representations of the above single-molecule counting data and of ELISA validation data
(black = pre-immunization; gray = week 4; white = week 5). Deviation of single-protein
counting measurements from ELISAs were at most 4.2%. The single-molecule counting
data and ELISA data were normalized to the pre-immunization time point.
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CHAPTER THREE: NANOGEL COATINGS FOR
IMPROVED SINGLE-MOLECULE DETECTION
SUBSTRATES
This chapter embodies a manuscript published in Journal of the Royal Society,
Interface on Feb 12, 2011. This chapter demonstrates that nanogel surface coatings can
improve the performance of single-molecule immunoassays as well as provide the best
surface coating for single-molecule detection studies, such as those that involve in vitro
binding and single-molecule biophysics. This work was a collaboration with the Elbert
Lab and the Jun Lab and is a testament to the atmosphere of collaboration that our
university harbors. The experiments were designed by Donald L. Elbert, Robi D. Mitra,
and me. Casey D. Donahoe synthesized the nanogel solutions and performed cell
adhesion time course assay. Young-Shin Jun and Daniel L. Garcia conducted the atomic
force microscopy studies. I created the nanogel-coated surfaces and carried out the single
molecule adsorption assays. I also performed the antibody binding assay, imaging and
analysis.
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ABSTRACT
Surfaces that resist protein adsorption are important for many bioanalytical
applications. Bovine serum albumin (BSA) coatings and multi-arm poly(ethylene glycol)
(PEG) coatings display low levels of non-specific protein adsorption and have enabled
highly quantitative single-molecule protein studies. Recently, a method was developed
for coating glass with PEG-BSA nanogels, a promising hybrid of these two lowbackground coatings. We characterized the nanogel coating to determine its suitability
for single-molecule protein experiments. Single-molecule adsorption counting revealed
that nanogel-coated surfaces exhibit lower protein adsorption than covalently-coupled
BSA surfaces and monolayers of multi-arm PEG, so this surface displays one of the
lowest degrees of protein adsorption yet observed. Additionally, the nanogel coating was
resistant to DNA adsorption, underscoring the utility of the coating across a variety of
single-molecule experiments. The nanogel coating was found to be compatible with
surfactants, whereas the BSA coating was not. Finally, applying the coating to a realworld study, we found that single ligand molecules could be tethered to this surface and
detected with high sensitivity and specificity by a digital immunoassay. These results
suggest that PEG-BSA nanogel coatings will be highly useful for the single-molecule
analysis of proteins.

INTRODUCTION
Single-molecule (SM) fluorescence microscopy studies hold great promise for
elucidating biological systems[78], but the non-specific surface adsorption of fluorescently
labeled proteins [60, 68],

antibodies [76], and bioconjugated nanoparticles[69]

is often a

significant source of experimental noise. Recently, low-background surface coatings have been
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developed that reduce protein adsorption to SM levels – levels at which a digital signal from
individual target molecules can be reliably quantified above the background of non-specifically
adsorbed molecules. For example, Tessler et al surveyed 12 different surface coatings and found
that the best performing of these, a covalently-coupled bovine serum albumin (BSA) coating,
allowed accurate protein quantification of as few as 55 molecules per 1,000 µm2 by SM antibody
binding. The low-background surface enabled target protein molecules to be tethered to the
surface and digitally detected with total internal reflection fluorescence (TIRF) microscopy and
without the need for fluorescence resonance energy transfer or two-color coincidence
detection.[76] Poly(ethylene glycol) (PEG) coatings that are highly resistant to protein adsorption
have also been developed.[49] Groll et al demonstrated that a monolayer of multi-arm PEG
covalently-coupled to a surface reduced protein adsorption to single-molecule levels, allowing
quantitative monitoring of protein folding by TIRF.[79]
Recently, Scott et al developed a method for coating surfaces with nano-scale hydrogels
(nanogels) formed by crosslinking multi-arm PEG to albumin.[43] Surfaces treated with these
nanogels displayed very low levels of protein adsorption, as measured by optical waveguide
lightmode spectroscopy (OWLS) and cell adhesion. The nanogel coating holds great potential for
SM applications because it is a hybrid of two good SM surface coatings and is thin enough ( 75
nm) to perform total internal reflection imaging.
Here we characterized nanogel-coated surfaces for use in SM protein studies. We
measured protein adsorption onto PEG-BSA nanogel coatings using a variety of proteins,
fluorophores, and labeling methods, as well as with DNA. We examined the resilience of the
nanogel coating to sodium dodecyl sulfate (SDS), a reagent commonly used in binding studies.
To assess the utility of nanogel coatings in the context of a real-world SM experiment, we
adapted the surface to perform digital measurements of antibody binding. Finally, we examined
the roles of capping steps, cross-linker molecules, and substrate coupling methods via adsorption
studies and atomic force microscopy (AFM). Our studies reveal that PEG-BSA nanogel surface
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coatings show substantially higher performance than previously characterized SM coatings and
should be of benefit to SM protein studies.

RESULTS
Nanogel coatings display lower protein adsorption than BSA or PEG coatings
We first sought to quantify antibody adsorption onto PEG-BSA nanogel-coated surfaces.
We generated covalently coated BSA surfaces, multi-arm PEG monolayer-coated surfaces, and
nanogel-coated surfaces within flow cells (Figure 12A), exposed them to fluorescently labelled
antibody, and quantified the adsorbed molecules by TIRF imaging. For adequate sampling,
images were acquired at five positions per surface, with independent surfaces analyzed in
triplicate. So, thousands of molecules were sampled to obtain each reported data point. (For
details see Supporting Information.)
We found that antibody adsorption onto uncoated control surfaces was too high to allow
single antibodies to be reliably resolved. In contrast, the BSA-, multi-arm PEG-, and nanogelcoated surfaces were highly resistant to antibody adsorption (Figure 12B). The BSA-coated,
multi-arm PEG-coated, and nanogel-coated surfaces adsorbed antibody at densities of 217, 117,
and 50 molecules per 1,000 μm2 image, respectively (Figure 12C). Thus, the nanogel-coated
surfaces adsorbed over four-fold less antibody than did the BSA-coated surfaces (p = 5.5 x 10-5, ttest) and two-fold less antibody than did the multi-arm PEG surfaces (p = 7.6 x 10-4, t-test). Cell
adhesion studies agreed with this finding and additionally showed that nanogel-coated surfaces
can perform well for 7-9 days compared to 1-3 days for covalently coupled BSA surfaces (Figure
S6).
By converting the observed molecular density on the surface to absolute mass density, we
determined that the nanogel-coated surfaces adsorbed 1.28 pg cm-2 of antibody. Thus, the PEGBSA nanogel coating is highly resistant to antibody adsorption, outperforming both the BSA-only
coating and the PEG-only coating (p = 4.0 x 10-6, ANOVA).
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Notably, the adsorption we

measured was ~1000-fold lower than the limit of detection of standard protein adsorption
measurement methods (e.g. OWLS and surface plasmon resonance).

Nanogel coatings resist adsorption of a variety of biomolecules
SM protein studies often involve labeled biomolecules other than antibodies, such as
enzymes and DNA molecules. Also, studies employ proteins that are labeled by a variety of
methodologies including single-dye labeling, multi-dye labeling, and fusion to fluorescent
proteins. We wanted to investigate the utility of the nanogel surface in a variety of contexts. To
this end, we interrogated nanogel coatings with Cy5-streptavidin (multi-labeled protein),
mCherry-E. coli methionine aminopeptidase (singly-labeled enzyme), and Cy5-thrombin binding
aptamer (singly-labeled DNA).
The protein, enzyme, and DNA were adsorbed at levels of 33, 573 and 225 molecules per
1,000 μm2onto the BSA-coated surface and 11, 75 and 19 molecules per 1,000 μm2onto the
nanogel-coated surface, respectively (Figure 13A-13F). For these three biomolecules, adsorption
onto nanogel coatings was significantly improved over a covalently-coupled BSA coating
(respectively: p = 0.025, p = 0.0002, p = 0.0001, t-test) (Figure 13G). Remarkably, the
improvement by the nanogel surface ranged from 3-fold to 12-fold, depending on the
biomolecule. So, the relative improvement by the nanogel coating is dependent on the size and/or
the biochemistry of the fluorescent biomolecule. The fact that the nanogel coating showed
improved performance across a variety of biomolecules underscores the potential utility of the
nanogel coating in a broad variety of SM studies.

Nanogel-coated surfaces are resilient to detergent
In solid phase in vitro binding studies, surfactants such as Triton X-100, Tween 20, and
SDS are commonly used for performing wash steps or to regenerate ligands after protein binding.
[75, 76] Therefore, we measured the resilience of PEG-BSA nanogel coatings to surfactant
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exposure. This was done by quantifying protein adsorption onto coated surfaces before and after
an SDS wash.
Surfaces were prepared, exposed to fluorescently labelled antibody, washed with 0.1 per
cent SDS, exposed to antibody a second time, and washed with SDS a second time. Imaging was
performed before and after each step to quantify the amount of attached antibody.
We found that the BSA coating was strongly affected by the SDS wash (Figure 14A, row
1) while the nanogel coating was mostly resilient (Figure 14A, row 2). The BSA coating
displayed a 4.1-fold increase in antibody adsorption after SDS exposure as compared to before
SDS exposure, whereas the nanogel coating displayed only a 1.7-fold increase in antibody
adsorption (Figure 14B). Thus, thin, PEG-BSA nanogel coatings should be superior to BSA
coatings for experiments that utilize surfactants.

Nanogel coatings are compatible with digital antibody binding experiments
Protein adsorption is an important parameter to consider when evaluating a surface for
SM protein experiments, but it is not the only one. If target molecules cannot be tethered to the
surface, or if the tethered molecules are not accessible for in vitro binding, then the method will
lack sensitivity of detection. Conveniently, nanogel coatings and BSA coatings contain surfaceexposed carboxyl groups (provided by the albumins), which allow for the near-universal tethering
of protein analytes via the use of a crosslinker (see Materials and Methods).[76] Making use of
this tethering method, we evaluated the compatibility of PEG-BSA nanogel coated surfaces with
digital antibody binding experiments.
We generated nanogel-coated surfaces and tethered target protein molecules labeled with
Cy3 to the surfaces. Then we bound the targets with Cy5-labeled antibody, washed away
unbound antibody, and used single-molecule TIRF to detect antibody-target binding (Figure
15A). We merged and processed the Cy3 and Cy5 channels (Figure 15B-15C), and correlation
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analysis showed significant levels of specific antibody binding (Figure 15D, see Supporting
Information for details).
By analyzing single molecules in the two channels, we observed that the antibodies
bound to their targets with high specificity: 68

1% of antibodies were bound specifically to

tethered, target proteins. We also found that the antibodies were able to bind to target molecules
sensitively: a substantial fraction of targets were bound by antibody (50.3

5.9%) and this

fractional binding is high compared to values we obtained previously using the covalently
coupled BSA surface (31

6%).[76] Notably, this is not the maximum fractional binding since

more will bind with higher antibody concentrations. Also, this level of fractional binding is a
lower-bound estimate, since some target molecules may be invalid (e.g. denatured proteins).
These results indicate that the nanogel coating allows targets to be immobilized and
bound with high antibody occupancy and low background. Thus, nanogel coatings are highly
suited for performing digital antibody binding experiments and should be generally applicable to
SM in vitro binding studies.

Investigation into the role of albumin in nanogel capping and cross-linking
Since the final steps of both the nanogel and the multi-arm PEG coatings involve capping
with BSA, we wanted to investigate to what extent the performance of the coatings depends on
capping. We performed SM adsorption measurements on nanogel and multi-arm PEG coatings
with and without capping steps. We found the nanogel coating behaved the same with and
without the capping step, whereas the protein resistance of the multi-arm PEG coating was reliant
on capping (Figure 16A). This is presumably because the uncapped nanogel, which is formed
from a partially polymerized solution containing a wide size-range of PEG-BSA complexes,
creates a surface that is more densely packed than that of the uncapped multi-arm PEG.
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Next, since the BSA molecules in the nanogel act as a multi-functional amine crosslinker,
we wanted to investigate whether a multi-arm amine-terminated PEG could be substituted for and
provide the same performance as BSA. We synthesized PEG-PEGOA nanogels by substituting
BSA with PEG-octoamine as has been described in previous work.[80] We applied this coating
and the PEG-BSA nanogel coating to glass and found that adsorption using the alternative
crosslinker detracted from the performance of the coating (Figure 16B). This result points to the
possibility that the PEG-BSA nanogel performance is contingent on a high molecular weight
crosslinking molecule – in this case, BSA.

Investigation into alternative coupling chemistries
We next explored the use of an alternative method for coupling nanogel solutions to glass
substrates with the hope of further reducing protein adsorption. In our previously described
experiments, we prepared surfaces by reacting the nanogel-containing solutions with
mercaptosilanated glass.[43] Coupling was achieved because the vinylsulfone groups in the PEG
portion of the nanogels react with the mercaptosilanated surfaces.

An alternative coupling

strategy is to react the amine groups in the BSA portion of the nanogel with an epoxysilanted
surface.
We prepared surfaces using this alternative coupling chemistry and measured protein
adsorption.

The epoxide-reacted nanogel coating adsorbed antibodies at a density of 103

molecules per 1,000 μm2 image (Figure 16B), so this surface adsorbed approximately two times
more protein than did the thiol-reacted nanogel surfaces (p = 5.6 x 10-4, t-test). We concluded
that thiol-coupled nanogels are more resistant to protein adsorption than epoxide-coupled
nanogels.
We were surprised to observe this difference in performance simply due to coupling
chemistry. To try to understand this, we used AFM to characterize their morphologies (see
Supporting Information). The standard, thiol-reacted nanogel surface displayed a homogeneous
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background (roughness value Rq = 0.480 nm), suggesting that the nanogels form a continuous
matrix on the surface (Figure 16C). The nanogels on the epoxide-reacted surface appeared to be
generally smaller and less homogeneous (roughness value Rq = 0.673; Figure 16D). By contrast
the multi-arm PEG coated surface formed a less-connected and non-homogeneous surface
(roughness value Rq = 0.823; Figure 16E). (Force curve analysis performed on the thiol-reacted
nanogel coating, the epoxy-reacted nanogel coating, and the multi-arm PEG coating showed
detachment forces of 19.087, 41.584, and 34.225 nN respectively.) We believe the high
connectivity of the thiol-reacted nanogels, reflected by roughness measurements, contributes to
the lower protein adsorption we observed.

DISCUSSION
Under the SM detection regime, nanogel coatings provided significantly lower protein
adsorption than BSA-coated or multi-arm PEG monolayer-coated substrates. Moreover, there was
a consistent gain in performance across three protein types and DNA, labeled by dyes and
fluorescent proteins. The nanogel surface was resilient to surfactant and was compatible with a
SM antibody binding experiment. We did not seek to optimize the fractional binding in these
immunoassays (which depends on antibody concentration), but for the concentration of antibody
used here, the fraction of ligands bound was at least as high as that obtained previously in digital
antibody binding experiments using BSA-coated surfaces.[76] Since the nanogel surface
outperformed the covalently-coupled BSA and the multi-arm PEG SM surfaces in adsorption and
resilience[76, 79], we conclude that the nanogel surface should be a useful coating for an array of
SM studies.
Surfactants can be useful in in vitro binding experiments, such as immunoassays, for
performing stringent washes and for un-binding antibodies from their epitopes in repeatedbinding experiments. A caveat is that surfactants can be detrimental to SM surface coatings. We
studied the effect of SDS surfactant on the nanogel coating and the BSA coating and found that
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the nanogel-coated surfaces were unaffected by treatment with surfactant while the BSA-coated
surfaces were substantially affected. This is surprising because the nanogels are partially
composed of albumin. It can be inferred that the BSA-only coatings undergo some level of
denaturation by the surfactant conditions. If this is the case, then the PEG macromolecules in the
nanogels may stabilize the albumin molecules within them and enable them to withstand the
denaturing conditions of the surfactant. This highlights another improved behavior that the
combination of albumin and PEG in a nanogel can confer over BSA-only surfaces. It is
promising, since it may enable lower-background and repeated-binding digital antibody binding
studies.
SM methods play a prominent role in the understanding of many biological systems.[8186] Looking forward, SM antibody-detection may provide strategies for parallel detection of
proteins. The recent development of massively parallel SM DNA analysis technologies by
Helicos Biosciences and Pacific Biosciences was facilitated by surfaces resistant to nucleic acid
adsorption.[87, 88] Promisingly, the nanogel coating characterized here shows similar levels of
background adsorption to that of such DNA technologies and also benefits from resilience to
wash steps. Therefore, PEG-BSA nanogels provide a thin, resilient coating technique that should
benefit SM protein analysis, and we hope that this coating methodology will spark an increase in
SM antibody binding studies.

MATERIALS AND METHODS
Synthesizing solutions of nanogels
PEG-BSA nanogel coatings were prepared using partially crosslinked solutions of eight
arm PEG and BSA. First, eight arm PEG-OH (PEG8-OH; MW 10,000; Creative PEGWorks,
Winston Salem, NC) was used to synthesize PEG-octovinylsulfone (PEGOVS) in a four-step
reaction, as described previously.[80, 89] PEGOVS and fatty acid-free BSA (Sigma-Aldrich, St.
Louis, MO) solutions were prepared at 20% (w/v) in phosphate buffered saline pH 7.4 (PBS) and
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sterile filtered with 0.22 µm syringe filters (Millipore, Billerica, MA). Assuming 36 reactive
amines per BSA (obtained from crystal structures), PEGOVS and BSA solutions were combined at
a 1:1 ratio of vinylsulfone to amine groups and reacted by incubation at 37°C, with rotation. The
progress of the reactions was followed by dynamic light scattering (DLS) until a mean effect
diameter (dPCS) of about 100 nm was achieved – generally ~6 hours. (At this step, the DLS
polydispersity index for the nanogel solution was 6.2, and the complexes in the nanogel solutions
had a standard deviation of ~20 nm.) The nanogel-containing solution was then diluted 1:1 with
PBS to 10% (w/v) and stored until use at -80 C. For long-term storage, nanogel solutions were
stored at -140 C. To generate PEG-PEGOA nanogels, the same protocol as above was used with
the exception that BSA was substituted by PEG-octoamine (PEGOA, MW 10,000). (For details,
see Supporting Information.)

Coating substrates with nanogels
Nanogel solutions were either thiol-reacted or epoxy-reacted to the glass substrates. The
glass substrates (40 mm diameter circles, #1.5) were obtained from Erie Scientific (Waltham,
MA). For the epoxide-reacted coatings, the substrates were epoxysilanated by the vendor. For
the thiol-reacted coatings, the coverslips were mercaptosilanated as follows. The coverslips were
washed 3x in diH2O and 3x in ethanol. Then they were etched with oxygen plasma at 100 W for
10 minutes (Femto, Diener Electronic, Royal Oak, MI). Coverslips were then washed 3x in
acetone. Mercaptosilanation was achieved by treating the glass for 1 hr at 25°C with a 5% (v/v)
solution of mercaptopropyltrimethoxysilane (MPTS, Sigma-Aldrich, St. Louis, MO) in acetone.
Surfaces were washed 3x in acetone and cured at 100°C for 25 min.
Substrates were coated with PEG-BSA nanogel-containing solutions in either a flow cell
(FSC2, Bioptechs, Butler, PA) or in a 60 mm diameter Petri dish (for cell seeding experiments).
Substrates were incubated in 10% nanogel-containing solutions for 1 h at 37° C. Substrates were
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washed with 600 µL PBS and capped for 1 h with BSA 50 mg/mL in PBS, 37° C. Unreacted
vinylsulfone or epoxide groups were then quenched with 1 M Tris pH 8.0, for 15 minutes at room
temperature. (A time course showed that quenching went to completion.) Coverslips were then
washed with 600 µL PBS.

Covalently coupled BSA-coated surfaces
The epoxide-reacted bovine serum albumin (BSA-coated) surfaces were generated by
reacting 50 mg/mL BSA, in PBS, to epoxysilanated glass coverslips within a flow cell for 1 h, at
37° C. Unbound BSA was washed away with PBS, and unreacted epoxides were quenched with
1M Tris pH 8.0 for 15 minutes at room temperature. Coverslips were then washed with 600 µL
PBS.

Multi-arm PEG monolayer-coated surfaces

The multi-arm PEG monolayers were generated by reacting 200 mg/mL PEGOVS ,in PBS,
to mercaptosilanated glass coverslips within a flow cell for 1 h, at 37° C. Coverslips were
washed with 600 µL PBS and incubated 1 h with 50 mg/mL BSA in PBS at 37° C.
Unreacted vinylsulfone groups were quenched with 1M Tris pH 8.0 for 15 minutes at room
temperature. Coverslips were then washed with 600 µL PBS.

SM adsorption measurements
Three different proteins and one DNA were used in the SM adsorption
experiments. These include polyclonal goat IgG labeled with multiple Cy5 fluorophores
(Abcam, Cambridge, MA), streptavidin labeled with multiple AlexaFluor 647
fluorophores (Invitrogen, Carlsbad, VA), E. coli methionine aminopeptidase fused to
mCherry fluorescent protein, and DNA thrombin binding aptamer labeled with a single
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Cy3 fluorophore (Integrated DNA Technologies, Coralville, IA). Each of the surfaces
under investigation was prepared within a flow cell (FSC2, Bioptechs, Butler, PA). An
uncoated control surface was generated by quenching an epoxysilanated glass coverslip
with 1M ethanolamine-HCl pH 8.0 for 30 minutes. Flow cells were fitted with perfusion
ports to allow for reagents to be passed over the surface by a custom vacuum pump. The
flow cells were washed with 600 µL PBS and loaded with 200 µL of 1 nM fluorescent
protein or DNA. The fluorescent molecules were incubated for 25 minutes in the dark at
room temperature, and unbound protein or DNA was washed off with 600 µL PBS.
Images were acquired and processed as described above. Standard deviations were
obtained from triplicate (for antibody) or duplicate (for all other molecules) surfaces.

Measuring detergent resistance
Each of the surfaces under investigation was prepared within a flow cell. Surfaces were
exposed to 100 ng/mL Cy5-labeled antibody for 25 minutes in the dark at room temperature to
assess initial levels of non-specific protein adsorption. Unbound antibody was washed out of the
flow cells with 600 µL PBS, and the flow cells were imaged. The flow cells were then exposed
to 0.1% sodium dodecyl sulfate (SDS) in PBS for 5 minutes at room temperature, washed with
600 µL PBS, and imaged. The flow cells were exposed for the second time to antibody for 25
minutes, to measure adsorption after SDS treatment. Surfaces were washed with 600 µL PBS, and
imaged. Finally, the flow cells were washed in 600 µL 0.1% SDS in PBS for the second time,
washed in 600 µL PBS, and imaged. Images were processed as described above. Standard
deviations were obtained by replicates on two separate surfaces.
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Digital immunoassays
Nanogel-coated surfaces were generated in a flow cell as described above. The antibody
binding experiment was performed as previously described.[76] First, the surface was activated
by 0.2 M 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) and 0.05 M Nhydroxysuccinimide (NHS) (Pierce, Rockford, IL) in sodium phosphate buffer pH 5.8 (SPB) for
10 minutes. The flow cell was washed with 600 µL SPB, and Cy3-labeled target protein (IgG
obtained from goat, Abcam, Cambridge, MA) was tethered to the activated surface for 10 minutes
at 100 ng/mL in PBS, in the dark. Unreacted crosslinking groups were quenched with 1 M Tris
pH 8.0 for 5 minutes. Then the surface was probed with Cy5-labeled antibody (anti-Goat IgG,
Abcam, Cambridge, MA) for 2 h at 100 ng/mL in PBS in the dark. The flow cell was washed
with 600 µL PBS and imaged at 540 nm and 635 nm. Images of Cy3 and Cy5 channels were
merged to determine the fraction of targets that were bound by antibody and the specificity of the
antibody for the targets compared to random binding. (See Supporting Information for details.)

ACKNOWLEDGEMENTS
We thank Jim Havranek and Ben Borgo for providing the mCherry-E. coli methionine
aminopeptidase fusion protein. We thank David Mayhew, Francesco Vallania, Jessica
Hoisington-Lopez, Maximiliaan Schillebeeckx, Michael Brooks, Scott Higdon, Todd Druley,
Xuhua Chen, and Yue Yun for helpful discussions. This work was supported by an Innovative
Molecular Analysis Technologies grant from the National Cancer Institute (1R21CA151197-01)
and a Technology Development in Epigenetics grant from the National Institutes of Health
(1R01DA025744-01).

57

FIGURES
Figure 12

(A) Schematic of three coating methodologies: bovine serum albumin (BSA) covalently
coupled to epoxysilanated glass, multi-arm PEG (PEG8) coupled to mercaptosilanated
glass, and PEG-BSA nanogels coupled to mercaptosilanated glass. (B) Antibody
adsorption onto uncoated, BSA-coated, multi-arm PEG-coated, and PEG-BSA nanogelcoated surfaces was quantified by TIRF imaging, and representative raw TIRF images are
shown. (C) Molecule counts of antibody adsorption per unit area. On the uncoated
surface, molecular density was so high that single-molecule counting was not possible.
BSA-coated, multi-arm PEG-coated, and nanogel-coated surfaces show decreased
antibody adsorption compared to the uncoated surfaces, with the nanogel-coated surface
performing the best. Error bars represent standard deviation of triplicate substrates.
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Figure 13

TIRF adsorption measurements for three types of biomolecules show improved
performance by nanogel coatings compared to covalently-coupled BSA coatings. The
nanogel coating reduces adsorption of (A-B) the multi-labeled protein, Cy5-labeled
streptavidin, (C-D) the singly-labeled enzyme, mCherry-E. coli methionine
aminopeptidase, and (E-F) the singly-labeled DNA, Cy5-labeled thrombin binding
aptamer. (G) Molecule counts of biomolecule adsorption per unit area onto (black bars)
covalently-coupled BSA coatings and (gray bars) nanogel coatings. Error bars represent
standard deviation of duplicate substrates.
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Figure 14

Nanogel-coated surfaces show resilience to a harsh surfactant environment compared to
BSA-coated surfaces. Coated surfaces were exposed to antibody, washed with sodium
dodecyl sulfate (SDS), re-exposed to antibody, and re-washed with SDS. Adsorption
measurements were obtained in between each step. (A) Raw TIRF images of (top row) a
covalently-coupled BSA-coated surface and (bottom row) a nanogel-coated surface over
the course of a 5-step antibody adsorption experiment. (1.) Surfaces prior to antibody
exposure. (2.) Surfaces after exposure to antibody. (3.) Surfaces after SDS wash. (4.)
Surfaces after second exposure to antibody. (5.) Surfaces after second SDS wash. (B)
The bar chart depicts the ratio of adsorption change after SDS exposure to adsorption
change before SDS exposure, i.e. (Step 4 – Step 3):(Step 2 – Step 1). Error bars represent
standard deviation of duplicate substrates.
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Figure 15

Nanogel coatings can be utilized for sensitive and specific, digital antibody binding. (A)
Cy3-target proteins were immobilized to a nanogel-coated surface and then bound by
Cy5-antibody. (B) Merged raw image of red and green TIRF channels (15 μm x 15 μm).
(C) Merged red and green TIRF channels after image processing. TIRF imaging was able
to detect a high number of binding events (yellow) in which target proteins (green) were
accessible to binding by antibodies (red). (D) The correlation between detection
antibodies and individual analyte proteins tethered to nanogel coated-surfaces indicates
high target protein accessibility and compatibility with TIRF detection.
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Figure 16

(A) Adsorption onto nanogel-coated and multi-arm PEG coated (PEG8) surfaces was
measured with and without the use of a final BSA capping step. The nanogel-coated
surfaces provided low antibody adsorption even without the capping step. (B) We
measured adsorption onto the standard nanogel-coated surface (PEG-BSA). We also
measured adsorption onto a surface coated with a nanogel solution formed with an
alternative crosslinker to BSA (PEG-PEGOA). Finally, we measured adsorption onto a
surface that was coated by coupling PEG-BSA nanogels to epoxysilanated glass (as
opposed to the standard, mercaptosilanated glass). We conclude that nanogel crosslinkers
and coupling chemistries can have a significant effect on adsorption performance. (C-E)
We assessed the topology of (C) the standard, thiol-reacted nanogel surface, (D) the
epoxy-coupled nanogel surface, and (E) the multi-arm PEG-coated surface. Cross
sectional height analysis is depicted in charts below. The thiol-reacted nanogel coating
created the most connected surfaces while multi-arm PEG monolayer coatings generated
the least connected surfaces.
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CHAPTER FOUR: SENSITIVE SINGLE-MOLECULE
PROTEIN QUANTIFICATION AND PROTEIN COMPLEX
DETECTION IN A MICROARRAY FORMAT

This chapter embodies a manuscript that is being peer reviewed for the journal
Proteomics. This chapter describes the development of a single-molecule antibody
microarray. The experiments were designed by Robi D. Mitra and me, and the
experiments and analysis were conducted by me.
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ABSTRACT
Single-molecule protein analysis provides sensitive protein quantitation with a
digital read-out and is promising for studying biological systems and detecting
biomarkers clinically. However, current single-molecule platforms rely on the
quantification of one protein at a time. Conventional antibody microarrays are scalable to
detect many proteins simultaneously, but they rely on less-sensitive and less quantitative
quantification by the ensemble averaging of fluorescent molecules. Here we demonstrate
a single-molecule protein assay in a microarray format enabled by an ultra-low
background surface and single-molecule imaging. The digital read-out provides a highly
sensitive, low femtomolar limit of detection and 4 orders of magnitude of dynamic range
through the use of hybrid digital-analog quantification. From crude cell lysate, we
measured levels of p53 and MDM2 in parallel, proving the concept of a digital antibody
microarray for use in proteomic profiling. We also applied the single-molecule
microarray to detect the p53-MDM2 protein complex in cell lysate. Our study is
promising for development and application of single-molecule protein methods because it
represents a technological bridge between single-plex and highly multiplex studies.

TECHNICAL BRIEF
Single-molecule protein detection has the potential to improve systems biology
and biomarker studies by providing highly sensitive quantification and a digital read-out.
Single-molecule protein techniques are achieved by several methodologies, but common
among them is the coupling of a single-molecule-sensitive detection modality with a
method for eliminating background fluorescence. In one approach, single-molecule
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protein quantitation is achieved through the dilution of antibody-target complexes in low
cross-section capillaries followed by detection by a sensitive photon detector[90]. In
another instance, femtoliter-volume wells are used to harbor single-molecule enzymelinked immunoassays[91]. Additionally, total internal reflection fluorescence (TIRF)
imaging has provided a platform for single-molecule quantification on planar surfaces.
TIRF analysis is especially promising because of the reliability and affordability of TIRF
optics and has been recently demonstrated for the digital quantification of proteins[76,
92-94] and lipopolysacharrides[95]. Despite the quantitative advantages of all of these
single-molecule methods, they are currently low throughput in that they can analyze only
one target at a time.
Microarrays are advantageous for proteome and interactome profiling because
they scale reliably for dozens of protein targets while relying on minimal reagent
volumes [57, 96] and so have proven valuable for quantifying the abundance of many
proteins simultaneously[97-100] and for detecting pairs of interacting proteins[101-105].
However, microarrays have neither the sensitivity of detection nor the precise digital
read-out provided by single-molecule methods. For these reasons, a single-molecule
assay for proteins that has the scalability of a microarray has been a major goal[92, 93].
Here we perform a proof-of-principle demonstration of a single molecule
antibody microarray. Our procedure begins by treating a glass substrate with a nanogel
coating that forms a protein resistant, hydrogel barrier of around 75 nm thickness[43].
The coating is activated with a cross-linker, making it reactive with the exposed lysines
of printed antibodies. Then, monoclonal capture antibodies are printed in specified
locations (fields) onto the substrates. Substrates are sealed to a flow chamber, the surface
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is passivated, and cell lysate is passed over the chip, binding target molecules to the
antibody fields. Then, the chip is exposed to detection antibodies and finally to
fluorescently-labeled streptavidin (Figure 17).
To obtain a single-molecule resolution read-out, total internal reflection
fluorescence (TIRF) imaging is performed. The microscope is directed to the locations of
the printed fields, and images are acquired within the center of each field. Nonoverlapping viewing areas are acquired within each printed field to obtain intra-field
replicates (multiple fields and multiple slides are imaged as well). Then, digital
measurements are obtained by counting fluorescence objects within the printed fields and
subtracting away background levels, which are measured outside of the fields.
We first sought to assess the performance difference between a digital and an
analog microarray in terms of limit of detection (sensitivity) and dynamic range. To do
this, we used the model assay that detects fluorescently labeled streptavidin by binding to
a biotinylated protein printed on the surface (to emulate a protein target captured by a
printed capture antibody). This model is a suitable estimate of performance since it
incorporates (1) the printing/attachment efficiency of the capture molecule, (2) the pulldown of a protein target from solution, and (3) the non-specific binding of the protein
target on the surface.
We obtained TIRF images for different concentrations of captured protein (Figure
18A). Then we analyzed the same raw data by two different methods to obtain two
standard curves – one by single-molecule counting (digital) and one by conventional,
ensemble intensity averaging (analog). The standard curve obtained from analog image
processing provided a dynamic range from 10 pM to 100 pM (Figure 18B), and the curve
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obtained from digital processing of the same data provided a dynamic range from 14 fM
(0.74 pg mL-1) to 33 pM (Figure 18C). So, given the same raw data, analysis by digital
counting provided greater sensitivity than ensemble averaging by around 3 orders of
magnitude. By combining the two standard curves (using the digital curve for the 14 fM
to 33 pM range and the analog curve for the 33 pM to 100 pM range), the hybrid digitalanalog curve provided around 4 orders of magnitude dynamic range. These results show
that single-molecule microarrays, by providing a high resolution view of the printed
antibody fields, can provide more sensitive detection than analog microarrays. Also,
single-molecule microarrays can allow for extension of dynamic range by combining
digital and analog standard curves. The dynamic range we observed here is well suited
for the analysis of biological systems and serum biomarkers.
We applied the single-molecule antibody microarray to analyze the regulatory
proteins p53 and MDM2. We generated p53/MDM2 microarrays as described above
using capture antibodies for p53 and MDM2. We benchmarked the microarrays using
dilutions of protein standards to validate each antibody pair individually and then tested
for cross-reactivity of the antibodies in a parallelized (dual-plex) assay (Supporting
Figure 1). To validate the single-molecule antibody microarray in a real world
application, we quantified p53 and MDM2 protein levels in a well-characterized cell
culture line, HCT116. This colorectal cancer line is known to respond to the DNA
damage agent 5-fluorouracil by up-regulating p53 and its downstream targets[106, 107].
The p53/MDM2 single-molecule microarray was exposed to cell lysate, protein levels
were detected in a single detection antibody step, and the slide was imaged and
analyzed.Both p53 and MDM2 protein levels fell within the digital range of the assay
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(Figure 19A). We found p53 protein expression to increase by 1.8-fold under DNA
damage conditions and MDM2 protein expression to increase by 6.6-fold under DNA
damage conditions (Figure 19B). These changes are in agreement with a recent study
using similar induction conditions of cancer cells (2.3-fold and 5.5-fold, respectively)
[108]. The results from this indicate the single molecule microarray is well suited for
cellular profiling. Promisingly, the microarray format should make the assay readily
adoptable to more highly multiplexed studies.
Antibody microarrays have been widely used for the discovery of proteome-wide
interactions[101-105], and we hypothesized that a single-molecule antibody microarray
could be used to detect a protein complex. To achieve this, we altered the detection step
of the p53/MDM2 microarray protocol by incubating only one detection antibody at a
time. In this way, we could quantify molecules located in the alternate field with respect
to the detection antibody. To establish the specificity of this protocol, we analyzed
solutions that contained one protein (e.g. p53) but lacked the other (e.g. MDM2). In these
controls, we observed low signal from two distinct immunosandwich assays: anti-p53
detection antibody binding to anti-MDM2 capture fields and anti-MDM2 detection
antibody binding to anti-p53 capture fields.
After establishing the levels of cross reactivity of the assay, we analyzed cell
lysate from HCT116 cells. By the two independent immunosandwiches, we observed
p53-MDM2 complex levels significantly above the controls (Figure 19C). The difference
in magnitude between the two lysate measurements is indicative of the difference in
affinity of the pairs of antibodies in the two different immunosandwiches. The mass of
signal in both of the interaction assays indicates the presence of a protein complex, which
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is consistent with the known protein-protein interaction between p53 and MDM2 in vivo
and in vitro [109, 110]. Thus, we present a model of how a single-molecule antibody
microarray may be used in protein-protein interaction studies.
Single molecule quantification of proteins should become of greater benefit to
disease diagnostics and systems biology by providing quantitation of rare proteins in
biological specimens. We used standard antibody microarray reagents, a nanogel-coated
surface, and TIRF imaging to provide duplex digital molecule counting in a planar format
that is suitable for higher degrees of multiplexing. As with all antibody microarrays,
scaling up to greater numbers of targets requires optimization to minimize crossreactivity. In this study, we focused on the platform itself – surface architecture, antibody
immobilization, and detection – which dictates assay performance to a large degree[111113]. Using a representative set of antibodies from a popular vendor, we were able to
detect with a digital read-out regulatory proteins p53 protein and MDM2 from crude cell
lysate and quantify small expression changes (1.8-fold). We also modified the assay to
demonstrate its utility in a protein-protein interaction study. The low femtomolar
sensitivity and 4-orders of magnitude dynamic range we observed provide a proof of
principle for the use of single-molecule antibody microarrays in larger-scale protein
quantification and protein-protein interaction studies.
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FIGURES
Figure 17

Scheme of the single-molecule antibody microarray method.
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Figure 18

(A) Representative TIRF images of fluoro-streptavidin captured onto the single-molecule
microarray printed with biotin capture fields. (B) Standard curve generated by analyzing
the data by conventional, fluorescence intensity averaging (analog processing). (C)
Standard curve generated by analyzing the data by discrete molecule counting (digital
processing). The single-molecule microarray enables higher sensitivity and higher
dynamic range than a microarray analyzed by analog processing.
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Figure 19

(A) Single-molecule protein expression of p53 and MDM2 in cancer cells, with and
without DNA damage induction. (B) Expression changes of 1.8-fold for p53 and 6.6-fold
for MDM2 are detected by three biological replicates. (C) Two different digital sandwich
immunoassays specifically detect the p53-MDM2 protein complex. Cell lysate and
control samples were analyzed by distinct immunosandwich assays: one using printed
p53 capture antibody, αp53C, with MDM2 detection antibody, αMDM2D, and the other
using printed MDM2 capture antibody, αMDM2C, with p53 detection antibody, αp53D.
The analysis of cell lysate provided a mass of signal above the levels of cross-reactivity
determined from controls, indicating the presence of the p53-MDM2 complex.
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CHAPTER FIVE: PROTEOMICS BY LINEAR MOTIF
ANALYSIS AND PARALLEL PEPTIDE SEQUENCING
This chapter embodies methods and results that can be found in two patents
(“Single Molecule Protein Screening,” PCT/US2009/066236, Mitra, RD, Tessler, LA,
and “Methods of Polypeptide Identification and Compositions Thereof,” US11/674,642,
Mitra, RD) as well as yet unpublished results. The in silico simulations for Dipeptide
Motif Analysis were performed by Robi D. Mitra. The dipeptide antibody ELISAs,
dipeptide correlation analysis, and the simulations for Parallel Peptide Sequencing were
performed by me.
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INTRODUCTION
Mass spectrometry and the immunoassay have been the workhorses of modern
proteomics, but each technology has a clear profile of strengths as well as weaknesses,
described in Chapter One. In short, mass spectrometry allows for the analysis of many
proteins but lacks the sensitivity for needed for most biomarkers. Immunoassays benefit
from high sensitivity, but their multiplexing ability is limited even in microarray formats.
Antibody microarrays have been mostly limited to analyzing dozens to hundreds of
targets because they rely on an antibody (or pair of antibodies) for every target of interest.
This “one-antibody/one-target problem” is a difficult issue for those interested in
proteome-wide analysis, since it implies the need to make approximately 23,000
individual antibodies, validate them, and eliminate their cross reactivity. A technology
with the sensitivity of an immunoassay but the multiplexed nature of mass spectrometry
would be beneficial.
The concept of obtaining sequence information from individual molecules has
spawned a revolution for DNA sequencing technologies, which perform DNA
polymerase or DNA ligase reactions on individual molecules to obtain base pair
information. We propose an analogous method that employs single-molecule detection to
obtain sequence information from proteins. This method is based on the idea that
individual amino acids or two amino acid (dipeptide) motifs may be detectable by
binding a probe such as an antibody (or aptamer, or engineered protein). We also
envision that such probes may be bound to targets, detected by TIRF imaging, and then
removed by stringent washing to allow for subsequent rounds of binding. In this manner,
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a small, “universal” set of antibodies (between 8 and 50) could be used to identify all
human proteins.
We propose two major ways in which this technology may be implemented. In
one embodiment of the technology, Dipeptide Motif Analysis, denatured protein
molecules are analyzed for the presence or absence of dipeptides within their polypeptide
sequence (Figure 20). In a second embodiment of the technology, Parallel Peptide
Sequencing, sequential amino acid information is obtained from peptide digests of
proteins (Figure 21). In both manifestations, polypeptides are analyzed by antibodies
during multiple rounds of binding and washing, and the digital binding signatures for
each molecule (enabled by single-molecule detection) reveal the unique identity of each
molecule.
Here we present proof of concept data to support and inform the further
development of Dipeptide Motif Analysis and Parallel Peptide Sequencing. The
computational analyses, immunization protocols, and antibody validations shown here
present hope for the development of high-throughput single-molecule protein detection.

DIPEPTIDE MOTIF ANALYSIS
Overview of the method
In Dipeptide Motif Analysis, denatured proteins are immobilized onto a surface
and probed by antibodies in multiple rounds of binding (Figure 20). The antibodies are
specific to common sequence motifs such as dipeptides. By analyzing the presence or
absence of dipeptides within proteins and doing so at single-molecule resolution, the
unique identity of the proteins as well as their abundances may be obtained.
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Theoretical Performance
Dipeptide Motif Analysis relies on bioinformatic fact that short, linear amino acid
sequences are moderately common throughout the proteome. For example, for many
dipeptides, the chance of that dipeptide being present in any given protein is
approximately 50% (Figure 22). For example, assuming that a complex mixture of
proteins is denatured and immobilized on a surface with single-molecule separation, an
antibody against a dipeptide motif (e.g. “proline-alanine”) should bind to ~50% of the
proteins (assuming 100% binding occupancy). After the removal of that antibody by a
stringent wash, a second antibody against a different motif (e.g. “serine-glutamate”)
should bind to a different 50% of the proteins. After around 40 successive rounds of
binding with different motif-recognizing antibodies, every molecule will have been
probed and will reveal a binding signature that is unique to that protein.
This is demonstrated by an in silico experiment that shows the number of
dipeptide antibody binding rounds that would be needed to uniquely identify all the
proteins in the human genome (Figure 23). With 40 dipeptide antibody binding rounds,
over 95% of the proteome can be uniquely identified. This in silico experiment also
simulates the performance using an optimal set of antibodies compared to a randomized
set. Those two sets behave similarly, probably due to the fact that the presence of
dipeptide motifs throughout the genome is relatively random (Figure 24). Therefore,
although 400 dipeptide motifs exist, with a set of only 40, one could, from an informatics
perspective, perform a full proteome analysis.
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After determining that the number of necessary dipeptide binding rounds is
feasible, we wanted to investigate whether Dipeptide Motif Analysis would be robust to
the type of errors expected in single-molecule experiments. For instance, 100%
occupancy may not be possible (we reliably obtained 70-80% occupancy in our single
molecule studies in Chapter Two). Additionally, non-specific binding could contribute to
errors in the binding signatures. By simulation, we showed with a 2.5% false positive
rate, the method can tolerate up to a 20% false negative rate. So, this method should be
robust to noise, including false positive and false negative binding events (Figure 25).

Generation of dipeptide motif antibodies
With the theoretical framework established for Dipeptide Motif Analysis, we
sought to investigate methods to generate and validate antibodies that could be used as
dipeptide probes. Antibodies cannot be generated with a priori knowledge of their
binding specificity. Instead, antibody recognition regions are generated by a biological
process that is inherently stochastic. To complicate this phenomenon, polyclonal
antibodies are comprised of a multitude of reactive species. Because of these
confounding elements, polycloncal antibody specificity can only be determined
empirically, by screening the antibody against a library of target molecules. As a result,
no test for specificity is universal because specificity, as defined by such experiments, is
only generalizable within the space of the test library.
Prior to deciding on dipeptide antibodies to generate, we sought to define the test
library, which comprises of exemplar true and false targets for each antibody. We
hypothesized that electrostatic forces would provide the strongest type of molecular
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interaction that forms antibody specificity, therefore we limited the exemplar targets to
those with specific electrostatic signatures. In this fashion we defined sixteen targets,
comprised of the exhaustive combinations of lysine (K), arginine (R), glutamate (E), and
aspartate (D) in dipeptide epitopes. These epitopes were synthesized to be internal to 9mer peptides and flanked by randomized amino acids. In order to ensure that “accidental”
exemplar dipeptides would not be formed, the amino acids flanking the dipeptide epitope
did not contain amino acids that were used within the epitope. For example, this
prevented the exemplar mixture X-X-K-R-X-X-G-G-C from being be contaminated with
X-R-K-R-X-X-G-G-C, which may have lead to a false positive recognition by the RK
antibody. These peptide mixtures were conjugated to carrier proteins and used in a rabbit
immunization procedure (see Methods).

Purification of dipeptide motif antibodies
After obtaining polyclonal antisera to the sixteen dipeptides, we began assessing
their specificity. We performed serum ELISAs for the KK, RR, EE, and DD antibodies
against the KK, RR, EE and DD target peptides. We took this as a test case because we
felt that if specificity was not possible between these cases, it would not be possible at all.
At this stage, the cross-reactivity ELISAs demonstrated very little specificity, with only
some specificity being produced from the KK antisera (Figure 26A).
We hypothesized that there may exist a high number of off-target antibodies
within the antisera that was masking the specificity of the antibodies. We presumed this
due to the complexity of the antigen (a highly randomized mixture containing only a
small consensus epitope). We tested this by purifying the antibodies from the antisera and
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subjecting them to multiple rounds of negative immuno-selection (see Methods). We
performed this immunodepletion by running the antibodies through multiple columns
containing peptide mixtures of the exemplar off-target dipeptide epitopes. Each antibody
was passed through columns removed antibody species that reacted with all fifteen other
dipeptide epitopes. Thus, after serial immunodepletion, the wash through from the
columns should have been enriched for those antibodies that react only with the true
exemplar dipeptide epitope.
After immunodepletion, the test set of KK, RR, EE, and DD antibodies showed
improved specificity (Figure 26B). To test whether the entire set of antibodies would
have any reactivity or specificity after purification and immunodepletion, I subjected
them to ELISA tests against all sixteen dipeptide mixtures, each with a dilution series of
antibody. All sixteen antibodies displayed reactivity in a concentration dependent manner
and all showed at least some degree of specificity (examplar curves in Figure 27). This
demonstrated the success of the immunization approach and that specific antibody
species remained within the polyclonal milieu after immunodepletion.

Analysis of antibody cross-reactivity
To analyze the global cross-reactivity all sixteen antibodies against the sixteendipeptide library, we used the highest concentration ELISA data points to create an
antibody specificity heatmap (Figure 28). This heatmap demonstrates that the antibodies
were highly specific in the epitope space of only two amino acids. Notably, most of the
antibodies showed specificity with fewer than three side reactions.
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The dipeptide antibodies achieved specificity to a startling degree. In one case
particular, the antibodies were able to identify glutamate-aspartate (ED) as distinct from
glutamate-glutamate (EE). This is impressive because these two dipeptides differ by only
a single carbon bond. Additionally, the anti-ED antibody was able to identify ED as
distinct from DE. This orientation specificity demonstrates the ability of the antibodies to
recognize the side chains in the context of the amine bonds that form the peptide.
Some dipeptides displayed more cross-reactivity than others. For instance, those
with lysine in the C-terminus tended to be more promiscuous in the second amino acid.
To investigate the ability to improve specificity after the initial immunodepletion, we
used the cross reactivity data to inform an additional immunodepletion step for an
antibody. An ELISA after this second, targeted immunodepletion shows that, although
affinity was reduced compared to the pre-depletion antibody, the cross reacitvities were
reduced (Figure 29). This is promising because it demonstrates our ability to tune the
polyclonal antibody mixtures.

PARALLEL PEPTIDE SEQUENCING
Overview of the method
In Parallel Peptide Sequencing a protein sample is trysin-digested, the resulting
peptides are immobilized by cysteines, a small number of antibodies (or other similar
probe) interrogates the N-termini the peptides, and then a chemical or enzymatic step
removes the terminal residues (Figure 21). After cycling between antibody binding and
cleavage, unique, identifying protein sequence information can be extracted. Then, by
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counting the number of sequence reads mapping to each protein, each protein in a sample
can be quantified.

Theoretical Performance
Parallel Peptide Sequencing relies on mapping sequence reads to a database of
polypeptides in the genome. One practical question is, what read-lengths are needed to
map back proteins reliably? This will dictate how many cycles of binding and cleavage
will need to be carried out. I performed an in silico experiment by sampling terminal
peptides from all of the proteins in the proteome (~23,000) given a particular read length
n. Then, I asked how many of those reads were unique within the human proteome
(Figure 30, blue).
By simulation, I found that with read lengths of eight amino acids and greater, one
could map over 90% of the proteome uniquely. Moreover, for a unique 10-mer, the
nearest peptide in the proteome is an average of 3.06 mismatches away. This means that a
10-mer can tolerate 1.5 mismatches within the read (15% error rate) and still be perfectly
mappable. For a 15-mer and 20-mer, the error tolerance is 21% and 24% respectively.
Taken together, this means that short reads can be highly mappable and robust to
sequencing errors.
To test the dependence on the types of peptide digestion, I performed simulations
of peptide digestion within the middle of proteins (30 residues and 60 residues internal)
as well as with trypsin digestion. With random protein digestion, the mapping ability was
slightly reduced. Here, a read length of eight could map 85% of the proteome (Figure 30,
red and green), down from 90%. When using a trypsin digestion however, the mapping
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ability was improved (Figure 30, blue). 8-mer reads from a trypsin digest could map 92%
of the proteome, and 6-mers are sufficient to map 89%. The performance improvement
by trypsin digestion is due to the fact that trypsin cuts at the C-terminal end of lysines and
arginines. Because every sequence read must be terminal or preceded by a K or R, the
information contained in each read is increased.
These simulations provide a feasible estimate for the number of cleavage rounds
that would be needed. However, the simulations assumed all twenty amino acids were
distinguishable from one another. Even though the data for dipeptide antibodies was
promising, it may be difficult to produce probes to detect and distinguish all twenty
amino acids since some amino acids are small and similar, such as glycine and alanine.
So next, I performed a more conservative simulation that assumed that only four types of
amino acids would be able to be distinguished: neutral hydrophobic, neutral hydrophilic,
acidic, and basic. To conduct this simulation, all proteins in the proteome were converted
into this four-letter sequence space.
The results of the in silico experiment using a quaternary alphabet show that
twenty residues would need to be sequenced in order to map 90% proteins uniquely
(Figure 30, orange). This is very promising for the possibility of Parallel Peptide
Sequencing, since it greatly reduces the challenge of finding a sufficient number of
terminal amino acid antibodies.

CONCLUSIONS
We have shown by simulation that proteomics by Dipeptide Motif Analysis and
Parallel Peptide Sequencing are feasible in terms of determination of protein identity, the
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required number of probe binding cycles, and robustness to sequencing error. For
Dipeptide Motif Analysis, we have additionally shown the generation of dipeptidespecific antibodies to be feasible.
Hurdles remain for both technologies. For Dipeptide Motif Analysis, it was found
to be difficult for the dipeptide antibodies to recognize peptides that were longer than the
peptides used in the immunization and to recognize peptides not attached to carrier
protein (data not shown). This inability to bind may be due to length dependence of the
antigen recognition region or context dependence of the carrier molecule. The inability to
bind may alternatively be due to secondary structure of peptides, but this is unlikely since
exhaustive combinations of heat, SDS, Triton X-100, and urea could not improve
binding. A valuable technological milestone would be to show that dipeptide antibodies
could recognize their respective epitopes in many sequence contexts. New antibody
generation techniques may be required for this goal[114, 115].
Smaller hurdles lie with Parallel Peptide Sequencing. A collaboration with Jim
Havranek and Ben Borgo of the Havranek Lab has been fruitful for the development of
proteins with engineered mutations that can bind to specific N-terminal amino acids (data
not shown). What remains to be shown is the effective binding to peptides that are on a
solid substrate. We have achieved success in conducting several types of cleavage
reactions in bulk experiments including Edman Degradation, Barrett’s Modification, and
substrate-dependent cleavage by an engineered enzyme. What is left to be shown is the
adaptation of one of these to a solid surface such as the nanogel surface.
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MATERIALS AND METHODS
Producing polyclonal antisera against dipeptide epitopes
Semi-random peptide mixtures containing dipeptide sequence epitopes were
generated by solid-phase peptide synthesis. The sequence of the peptide mixtures (from C
to N termini) was X-X-epitope-X-X-G-G-C. Each mixture contained one of the sixteen
following epitopes: KK, KR, KE, KD, RK, RR, RE, RD, DK, DR, DE, DD, and EK, ER,
EE, ED. Positions labeled X denote positions in which equal amount of all twenty amino
acids were used in the synthesis step. The G-G sequence was used as a spacer between
the variable region of the peptides and the carrier protein, and the terminal cysteine acted
as the linker for carrier conjugation. Each of the sixteen dipeptide mixtures was
conjugated to carrier protein and used to generate antisera in rabbits. Two rabbits were
used per dipeptide epitope protocol for assurance of immune response. All peptide
synthesis and animal protocols were conducted by 21st Century Biochemicals, Inc.
(Marlborough, MA).

Affinity purification
The sixteen antisera were subjected to affinity purification to separate the
antibodies from serum proteins. Columns were prepared with resin coated in the targeted
peptide mixture and antisera was bound, washed, then eluted. For example the KK
antisera was bound, washed and eluted from a column packed with X-X-K-K-X-X-G-G-C
resin.

85

Immunodepletion
We synthesized sixteen negative selection (immunodepletion) peptide mixtures
with which to remove off-target antibody binding and to maximize the specificity within
this group of sixteen antibodies against the sixteen epitopes. These peptides were of the
sequence Z-Z-epitope-Z-Z-G-G-C, where epitope denotes one of the sixteen dipeptide
epitopes and Z denotes randomized flanking residues that excluded the amino acids K, R,
E and D. For each affinity purified antibody, we depleted it against beads containing
fifteen other dipeptide epitope negative selection peptides. These depletions were split up
over four columns to provide enough exposure of all negative selection peptides.
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FIGURES
Figure 20

A schematic of digital proteomics
by Dipeptide Motif Analysis. (A)
Millions of denatured proteins are
covalently attached to a substrate.
(B) In successive rounds of binding
and washing, a set of antibodies
recognize dipeptide motifs internal
to the proteins. Zeros indicate the
absence of a motif and ones indicate
the presence of a motif. (C) Binding
signatures are mapped to unique
polypeptide

sequences

proteome database.
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Figure 21

Trypsin or
random digest

A schematic of digital proteomics by Parallel Peptide Sequencing. A protein sample is
digested and peptides are covalently attached to the analysis substrate. The N-termini of
peptides are probed by rounds of probe binding and washing. After the terminal amino
acid is identified, the terminus is removed by chemical or enzymatic cleavage, and the
next amino acid is identified.
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Figure 22
A

B

Informatics analysis shows that dipeptides are present at between 0%
and 80% frequency in the proteome. A large number of dipeptides are
present at frequencies between 45-55%, so they should be highly
suited for maximum protein discrimination by Dipeptide Motif
Analysis.
(A)

Histogram of the number of dipeptides (out of 400) which are

present in polypeptides in the proteome. For example, ~20
dipeptides are present at a frequency of 0.45 – 0.5 in the proteome.
(B)

Example of dipeptides present between 0.45 and 0.55 in the
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'PL'
'TL'
'LK'
'LT'
'SP'
'PS'
'AG'
'AV'
'EA'
'VS'
'DL'
'KL'
'PG'
'GA'
'SV'
'PA'
'SR'
'GG'
'SE'
'QL'
'AE'
'RR'
'EK'
'IL'
'PP'
'LD'
'VA'
'KE'
'PE'
'TS'
'RS'
'FL'
'RA'
'ST'

proteome. These would be ideal for Dipeptide Motif Analysis. For example, “GG” is
present in 50% of the proteins in the proteome and absent in the other 50%.
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Figure 23

Simulation showing the fraction of proteins in the proteome that would have a unique
dipeptide motif binding signature using an optimal pool of dipeptide probes (blue line)
and a random pool of dipeptide probes (green line). (Mitra, unpublished)
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Figure 24
A

B

The presence of dipeptide motifs is mostly uniform throughout the proteome. A
clustering of the presence (red) and absence (blue) of the 400 dipeptides across ~23,000
proteins shows that no two dipeptides co-occur substantially. The only co-occurance is at
the level of individual amino acids. For example, proteins that contain a tyrosine are more
likely to contain tyrosine-containing dipeptides than proteins without tyrosine.

(B)

Hierarchical clustering based on presence/absence Hamming distance shows no
substantial clustering.
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Figure 25

Simulation of unique mapping for Dipeptide Motif Analysis including a 2.5% false
positive error rate and varying false negative error rates (Mitra, unpublished). Up to a
20% false negative rate is tolerable for a 100 motif binding assay.
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Figure 26

ELISAs performed on serum and on purified/immunodepleted antibodies for four test
cases (KK, RR, EE, and DD motifs). Perfect specificity of antibodies for their respective
antigens would be indicated by a descending diagonal line. Serum from immunized
rabbits showed little specificity. After antibody purification and immunodepletion,
specificity was achieved.
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Figure 27

Five ELISA that were representative of the sixteen ELISAs to test specificity of the
dipeptide antibodies against a panel of sixteen dipeptides.
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Figure 28

Summary of specificity of sixteen antibodies against sixteen dipeptides. Red boxes along
the descending diagonal indicate perfect specificity, and red boxes off of the diagonal
indicate cross-reactivity. Most antibodies showed cross reactivity with fewer than three
peptides.
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Figure 29
A

B

Specificity of the polyclonal antibodies is “tunable.” Cross-reactivity profile by ELISA
for the Anti-KE antibody before and after a second round of immunodepletion. (A) Initial
purification and immunodepletion yielded some cross-reactivity with KD, KR and KK.
(B) After a second round of immunodepletion against KD, KR and KK, the crossreactivity (as well as the affinity) was reduced.
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Figure 30

Computer simulations of Parallel Peptide Sequencing show that only 8 residues need to
be sequenced (with full, twenty amino acid resolution) in order to uniquely map reads to
90% of the human proteome (blue). With the amino acid sequence reduced to a
quaternary alphabet, 20 residues need to be sequenced to uniquely map reads to 90% of
the human proteome (orange). Sequencing within the middle of a protein reduced
mappability slightly (red and green). Sequencing from trypsin-generated peptides
improves mappabilitiy (purple). The remaining 10% of the proteome is difficult to map
due to homology among small sets of proteins.
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CHAPTER SIX: CONCLUSIONS AND FUTURE
IMPLICATIONS
The biomedical diagnostics world is moving toward single-molecule detection
faster than ever before. Before the initiation of this thesis, only one group had examined
single-molecule detection in an immunoassay, and that was not in a chip-based/solidphase format. Since the publication of our study in Analytical Chemistry, at least nine
other groups have published on the subject with one of them being a venture capital
funded company. I believe this trend will continue, that more academic and commercial
laboratories will focus on single-molecule immunoassay applications, and that existing
biotechnology companies will begin to adopt these techniques into their platform
technologies. For instance, one DNA sequencing company, Pacific Biosciences, has
begun exploring the translation of proteins with single ribosome resolution.
Single-molecule immunoassays are increasing in number, but there is still a dearth
of science and engineering progress in the area of single amino acid and dipeptide
recognition. Although two groups have written articles on prospective research in
sequence and motif analysis [114, 115], only one group has published a molecule, an
aptamer, than can detect short peptide motifs (tripeptides) [116]. Thus, I believe our lab
and our university collaborators hold the scientific know-how, funding, and intellectual
property rights to develop the proteomic technologies introduced in Chapter Five into
research and commercial tools.
The findings in this thesis can be applied immediately to the quantification of
proteins in cell lysate and serum. For experiments in which multiplexing is not necessary,
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the direct immobilization method presented in Chapter Two provides an easy and
sensitive way to monitor single-molecule antibody binding and could be used to monitor
the in vitro binding of other interacting molecules. The nanogel surface coating
characterized in Chapter Three should provide the biophysics community a way to
conduct in vitro binding assays with higher occupancy and lower background. The
single-molecule antibody microarray in Chapter Four will allow multiplexed experiments
that are at least as sensitive as their analog counterparts, and with optimization, may be
made more sensitive. Moreover, microarray facilities can easily adapt their printing
methods to suit the nanogels protocol.
Protein analysis has proven to be a challenging and highly rewarding subject. This
thesis has given me the chance to learn much in the areas of microscopy, surface
chemistry, antibody development, and biochemistry. My enthusiasm for this line of
research has only increased over my graduate career, and I hope this thesis inspires others
to apply and develop protein analysis methods and single-molecule detection methods in
biology and biomedicine.
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APPENDIX ONE: SUPPLEMENTAL INFORMATION

Supporting Information
for
“Protein quantification in complex mixtures by solid phase
single-molecule counting”

Analyzing Images by Iterative Thresholding
We developed software to determine the positions of single fluorescent molecules
that overcomes the limitations of the nonuniform illumination region inherent to the
Nikon TIRF Illumination. We created a Metamorph Journal that reads in a 12-bit TIFF
and acts as follows. We iterated over intensity thresholds from 0 to 4,050 by increments
of 50. For each intensity threshold, we defined objects as sets of pixels that 1) have
intensity values are greater than the threshold, 2) are contiguous with other pixels within
that object and 3) comprise an area between 2 and 20 pixels. We found the limits of 2 and
20 to give the best precision. Then for each object found at each intensity threshold, we
outputted the X-Y locations of the object centroids. We imported this set of 2-D points
into MATLAB. Then we created a binary output image, of ones and zeros, which
contained a 3 x 3 pixel square of ones centered on each of the 2-D points. These binary
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squares were used to represent the locations of fluorescent molecules for analyzing their
positions and abundance.
To measure sensitivity and specificity of iterative thresholding (IT), we obtained
several raw images of Cy5 antibody molecules, analyzed them by IT and by single value
thresholding (SVT), and outputted analyzed versions using each method. To obtain
sensitivity, we measured the fraction of objects present in the SVT image that were also
present in the IT image. To obtain specificity, we measured the fraction of objects present
in the IT image that were present in the raw image. False positives with respect to the raw
image we identifiable by the lack of likeness to a Gaussian point-spread function.

Measuring Protein Detection Efficiency
For analyzing the dual-color assays, the acquired Cy5 image (antibody) and the
corresponding Cy3 image (protein) were processed by the IT algorithm into binary
images. Then, we chose a 316 pixel x 316 pixel (31.6 µm x 31.6 µm) region from the
Cy5 and Cy3 images to calculate the antibody-protein correlation. The correlation
between red and green channels was calculated as follows (Equation 1):

316 316

C

Ri , j Gi , j
i 1 j 1

.

(1)

Here, R and G are matrices of ones and zeros, representing the binary image of size 316 x
316 pixel2. To correct for stage shifting, we allowed the Cy5-Cy3 image pair to be offset
with respect to each other in order to find the alignment that produced the maximum
correlation (the true alignment). Once the true alignment was found, our software counted
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the number of proteins that overlapped antibodies and divided that by the total number of
proteins. We defined this ratio as the fractional accessibility or binding efficiency.

Testing for Random Correlations and Specificity of Binding
To determine whether the Cy5-Cy3 image correlation was a random event, we
compared the correlation derived from Equation 1 to the background distribution of
correlations for Cy5-Cy3 image pairs that were offset in the X and Y directions. To do
this, we chose a 316 x 316 pixel2 region from the Cy3 image as the “base”. We then
computed the correlation of the base with regions of the Cy5 image that were misaligned
by a translational offset. We scanned offsets between -100 to +100 pixels (with respect to
the true alignment) in both the X and Y directions. After these 40,000 correlations were
computed, they were plotted as a function of the X and Y offsets. To interpret the Z-axis
of the correlograms, level surfaces correspond to the background distribution of
correlation values, and peaks correspond to correlations that are significantly nonrandom.
In binding experiments in which the antibody was specific for its target (Paper Figure 2),
a high peak was seen around the offset (0, 0). Therefore correlation for the true alignment
was nonrandom, and binding was specific. By contrast, when a nonmatching protein
target was used, no peak appeared (Figure S3), indicating randomness between Cy3 and
Cy5 channels (and no specific binding).
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Estimating Nonspecific Binding Based on the Observed Antibody Density
We used the total number of antibodies remaining on the surface after washing to
estimate the frequency of antibody-ligand correlations that occurred merely by chance
overlap of molecules – the false positive (FP) rate. We define the FP rate as the
probability that a randomly chosen pixel will be within a radius 2.5 pixels from an
antibody pixel. This probability follows a Poisson process, where the parameter lambda is
the frequency of antibody pixels out of the total number of pixels. Therefore, for the
number of antibodies on the surface A, and total pixel area of the image T,

FP 1 exp(

2.52 A
)
T

(2)

Quantifying Total IgG in Rabbit Serum by ELISA
The three rabbit serum samples (see Methods) were used as coating antigens. The
detection antibody was polyclonal anti-rabbit antibody conjugated to alkalinephosphatase (Abcam, Cambridge, MA). Polystyrene microtiter plates (Immulon 2HB)
were obtained from Thermo Fisher Scientific (Waltham, MA). Washes were performed
using Labsystems Multidrop 384 (Beckman Coulter, Fullerton, CA). Detection of the
fluorogenic substrate, (4-methylumbelliferyl phosphate, Sigma Aldrich, St. Louis) was
performed on the microtiter plate flourimeter Synergy HT (Biotek, Winooski, VT).
An indirect enzyme-linked immunosorbent assay (ELISA) was performed as
described.[117] For each serum sample, two dimensional titrations were performed to
determine the optimal dilutions of coating antigen and detection antibody. A dynamic
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range of detection that spanned the signals of all three serum samples was achieved using
the following dilutions. Coating antigens – 1:64,000. Detection antibody – 625 ng/ml.

SUPPLEMENTAL FIGURES
Figure S1.

Demonstrating single-antibody detection. To test whether fluorescence objects were in
fact single molecules, we mixed antibodies of two different colors together and quantified
number of instances in which we observed two overlapping objects on the surface. We
observe no significant overlap (p = 0.73 Fisher’s Exact Test) between antibodies labeled
with (A) Cy3 or (B) Cy5 when (C) images are merged (scale bar = 10 µm). This
indicates that each fluorescence object represents a single antibody molecule.
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Figure S2

Attachment efficiency. The EDC/NHS heterobifunctional crosslinking system can
effectively activate BSA molecules on the surface to immobilize target proteins. (A) The
number of protein molecules attached to the surface per 2,000 µm2 with and without
EDC/NHS surface activation. (B) Images of protein molecules attached to the surface
(top) without EDC/NHS surface activation and (bottom) with EDC/NHS (scale bar = 10
µm).
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Figure S3

Negative control for binding. When we perform protein detection using a nonspecific
target protein, the correlogram analysis shows a random distribution of correlations,
indicating no specific binding.
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Figure S4

Dissociation of surface-bound antibody:target complexes is insignificant over 48
hours. We performed antibody binding onto immobilized Cy3-targets and counted the
number of antibody:target complexes. We washed the flow cell over 48 hours and
analyzed the number of complexes every 8 hours. Here we plot the number of complexes
over time. We do not see a decay of the number of antibody:target complexes over time,
so there is likely an antibody-surface interaction.
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Figure S5
Efficient multiplexing. Here we illustrate an efficient strategy for multiplexed protein
detection in which n proteins may be quantified in

log 2 n
c

binding rounds, where c is

the number of independent fluorescence channels used for antibody detection. This
logarithmic encoding is based on the method by Gunderson et al, used to decode beadbased random microarrays.[56] Here we describe a 7-plex assay, using 1 fluorescence
channel, as a small-scale example.

First, each protein is assigned a unique
digital

signature.

Next,

fluorescent

antibodies for each protein are pooled
into combinations that are determined by
the columns of the digital signatures. (In
the example above, the three columns of
the signatures dictate the compositions of
the

three

“antibody

pools”.)

Then,

immobilized proteins are probed by one
antibody pool per binding round. In each
binding round, proteins of different
species are bound and detected. In
between binding rounds, antibodies are
stripped. After probing with all of the
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antibody pools (three in this example), the history of binding at each position on the slide
is analyzed. In this manner, each position on the flow cell becomes represented by a
binding signature. Finally, the pre-assigned digital signatures are used to decode the flow
cell positions into protein identities. Moreover, the number of occurrences of each
signature is counted to determine protein abundance.
To illustrate the decoding procedure, in this example there are two positions on the
flow cell that have the binding history 1-0-0 (i.e. bound in round 1, unbound in round 2,
and unbound in round 3). This signature corresponds to Protein 4, so the number of
instances of that signature on the flow cell (two), indicates the abundance of Protein 4.
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Supporting Information
for
“Nanogel surface coatings for improved single-molecule detection substrates”

Design of SM antibody adsorption experiments
To quantify the non-specific adsorption of fluorescent antibody onto coated
surfaces, we generated coated surfaces in flow cells and then exposed them to dilute
solutions of labeled antibody. We visualized the antibody molecules that adsorbed to the
surfaces by a total internal reflection fluorescence (TIRF) microscope that is capable of
detecting single fluorescent molecules.
Several steps were taken to enable the accuracy and precision of the antibody
adsorption measurements. We used antibodies that were labeled with an average of eight
fluorophores, so that almost all were fluorescently labeled.

This can be seen by

approximating the dye-labeling reaction as a Poisson process. Eq. 1 is used to compute
the fraction of antibody molecules that were labeled in our experiments:

k

P( N

k)

e
k!

Eq. 1

If λ = 8 (the labeling efficiency reported by the supplier), then only ~0.03% of the
antibody molecules contained no label (k = 0, in the equation above), and so ~99.97% of
the antibodies were labeled with at least one dye.
To maintain precision, all surfaces in an experiment were exposed to antibody
pipetted from an identical aliquot.

This eliminated variation otherwise caused by
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antibody dilution errors. We found that despite using low-protein-binding tubes for
storing the antibody, there was noticeable loss of antibody within the storage aliquots
over time due to adsorption to the surfaces of the tubes. To minimize this variation, we
parallelized experiments whenever possible. Because of the limited number of flow cells
at our disposal, there were some experiments for which we could not test all surfaces and
replicates simultaneously. In these cases, common control surfaces were included in the
experiments to remove (by normalization) the variation caused by antibody loss in
storage tubes.

SM imaging
SM imaging was performed on a Nikon TE-2000 inverted microscope fitted for
total internal reflection fluorescence (TIRF) (Nikon, Melville, NY). A 640 nm, 40 mW
laser was used for fluorescence excitation of Cy5 dyes, and a 532 nm, 75 mW laser was
used for excitation of Cy3 dyes. (Cube-40C and Compass 215M, Coherent, Santa Clara,
CA). Illumination of the surface was controlled through a computer animated shutter
(Prior Scientific, Rockland, MA). The laser beams were coupled into one end of an
optical fiber cable with the other end of the cable attached to the TIRF illuminator.
Before reaching the objective, the beams were passed through a D635/30 band pass filter
for the red channel and HQ545/30 band pass filter for the green channel (Chroma,
Brattleboro, VT). Objective type total internal reflection was achieved through a 60x
TIRF oil objective with numerical aperture 1.49 (Nikon, Melville, NY). The surface
modifications were performed in a glass flow cell (FSC2, Bioptechs, Butler, PA) which
was mounted onto the microscope stage. The incident angle of the laser beam was
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adjusted to generate total internal reflection, which creates an evanescent wave that
decays exponentially at the glass-water interface into the flow cell to a distance of about
300 nm. To prevent fluorophore photobleaching and blinking, an oxygen scavenger
system based on glucose oxidase and catalase and a blink-reduction system (Trolox) was
added to the flow cell prior to image acquisition.[77] Emitted photons from the labeled
antibody molecules were collected by the objective and passed through a dichroic mirror
(custom Cy3/Cy5, Semrock, Rochester, NY) and emission filters (LP02-647RU-25,
Semrock, Rochester, NY for the red channel, and HQ610/75, Chroma, Brattleboro, VT
for the green channel). Light from each of the channels was then detected sequentially by
a charge coupled device (CoolSnap ED, Roper Scientific, Tucson, AZ) which imaged a
140 µm by 100 µm (1400 px x 1000 px) region of the surface. Images of the flow cell
surface were acquired with 0.5 second exposure. For adequate sampling, images were
acquired at five positions across the length of the 3 mm x 35 mm flow-cell with
independent surfaces analyzed in duplicate or triplicate. Therefore, between 500 and
10,000 molecules were sampled for each reported data point.

Image processing
We used custom image processing software described previously to determine the
number of fluorescent molecules present on the surface.[76] Two notable traits of the raw
data are non-uniform illumination across the field of view (due to our TIRF apparatus)
and fluorescence objects of different sizes (due to multi-labeling of protein and antibodies
by fluorophores). The image processing described below has been validated to normalize
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for both non-uniformities; we normalize for non-uniform illumination, and we filter out
molecules that are overlapping other molecules.
Briefly, we employed a Metamorph Journal (Molecular Devices, Downington,
PA) that reads in a raw, 12-bit TIFF image and performs iterative intensity thresholding
to determine fluorescence objects in an image. We iterated over intensity thresholds by
increments of 50, with each iteration defining a threshold for local intensities (“local
threshold”). (For the Cy5 channel we iterated over the range of 175 to 4025, and for the
Cy3 channel, we iterated over the range of 200 to 4050. This normalizes for emission
intensity differences between the two channels.) For each local threshold, we defined
objects as sets of pixels that: 1) have intensity values that are greater than the local
threshold, 2) are contiguous with other pixels within that object, and 3) comprise an area
between 2 and 16 pixel2 (20 and 160 nm2). The contiguity requirement creates a list of
potential objects while the area requirement filters out those that are likely to be
combinations of multiple objects. For each object found at each local threshold, we
outputted the X-Y locations of the object centroids. This set of 2-D points was imported
into a custom MATLAB script (MathWorks, Natick, MA), which created binary images
of the objects. These objects were counted by the software to generate a measure of
molecules per unit area.

Correlation analysis
To determine whether fluorescence objects in the red and green channels
(antibodies and target proteins) were overlapping significantly or simply by chance,
correlogram analysis was performed as previously described.[76] We found that XY
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translations were perfectly suited to identify proper alignment, and additional channel
distortion played a negligible role. In brief, the red and green channel images were first
analyzed (see Image Processing) to produce binary matrices, indicating the positions of
each fluorescence object. A sub-matrix of the green channel was chosen as the reference
matrix and compared to a sub-matrix of the red channel, using the correlation function

316 316

C
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Eq. 2

in which R and G are sub-matrices representing 316 x 316 pixel sub-images of the red
and green images, respectively. This correlation was determined for truly-aligned submatrices of the red and green channels, as well as for red and green sub-matrices that
were mis-aligned by a translational offset. We sampled offsets between -100 pixels and
+100 pixels in X and Y dimensions with respect to the true alignment. A correlogram
was created by plotting the correlation C as a function of X and Y translational offsets. A
distinguishable peak near the origin indicates that the true alignment produced a
correlation that would not be expected given a random overlapping of objects.
Since no anti-photobleaching system is perfect, some molecules on the surface
may be missed. Any of these false negative events would reduce the number of observed
overlaps. Thus, the height of the peak in the correlogram is a lower bound of the true
level of correlation.
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Cell adhesion assay and time course
Here we analyzed the nanogel-coated surfaces by measuring cell adhesion. In this
method, the surface is exposed to fibroblast cells in medium containing physiological
levels of serum proteins (100 mg/mL). Because fibroblasts require the adhesion of serum
proteins before they can attach to a surface, cell growth serves as a measure of the
amount of adsorbed serum protein.
We generated BSA-coated and nanogel-coated surfaces, exposed them to
fibroblasts in serum-containing growth media, and imaged the surfaces by phase contrast
microscopy the next day. Images of the surfaces after cell seeding is shown in Figure S1,
column 1. Fields of view were chosen to depict the region of each surface with the most
cell adhesion. The uncoated control surfaces were covered with a monolayer of cells after
only one exposure to cells and medium. In contrast, the BSA-coated surfaces were
largely free of cells, with cells covering ~1% of the surface while PEG-BSA nanogelcoated surfaces (both epoxide- and thiol-reacted) displayed virtually no cell adhesion.
Therefore, although the cell adhesion measurements provide less dynamic range than the
SM antibody adsorption measurements taken previously, we observed remarkably similar
results between the methods.
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Figure S6

We next wanted to investigate the stability of the surfaces. We performed a time
course of cell adhesion by continuing to expose the surfaces to serum proteins and
fibroblasts every 3 days, until we observed cells covering a significant portion of each
surface. Images of the surfaces over the time course (days 4, 7, and 10) are shown in
Figure S6, columns 2-4. BSA-coated surfaces maintained low adhesion until after the
second seeding (day 4), at which point they were completely covered with monolayers of
fibroblasts. In contrast, the PEG-BSA nanogel-coated surfaces resisted serum protein
adsorption through three rounds of seeding. On day 10, after the 4th cell seeding, the
thiol-reacted nanogel surfaces lost their resistance to cell adhesion and were found to
contain large networks of cells. The epoxide-reacted nanogel surfaces also began to fail
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after the 4th seeding. Therefore, the BSA coating was stable for approximately 4 days
whereas the nanogel coatings resist adsorption of serum protein mixtures for
approximately 10 days before deteriorating. We determine that the nanogel surface will
be more useful than BSA surfaces in solid-phase protein studies that require extended
durations.
Despite the differences between the SM adsorption assay and the cell adhesion
assay we were happy to find that data at the first time point were similar between the two
methods. This lends support to the relevance of the SM adsorption measurements to
higher concentrations.

Atomic force microscopy
AFM (Nanoscope V multimode SPM, Veeco Instruments) was utilized in tapping
mode. We examined morphologies of the PEG-BSA nanogel-coated samples on both
epoxysilanated and mercaptosilanated glass surfaces without BSA capping. In situ
surface imaging was performed using silicon nitride tips (NP-10, Nanoprobe, Veeco)
with a nominal spring constant of 0.32 N m-1, and scan rates of 1-1.2 Hz. Force curve
analysis was performed with a spring constant of 40 N m-1, Poisson’s ratio of 0.5, and
semi-vertical tip angle of 25°. Roughness analysis and force curve analysis were
performed on two replicate surfaces for each coating type.
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Supporting Information
For
“Sensitive single-molecule protein quantification and protein complex detection
in a microarray format”

MATERIALS AND METHODS
Coating glass with nanogel
The microarray chips were formed from a glass coverslip (Fisher Scientific,
Pittsburg, PA) that was treated with nanogel coating by epoxy coupling[118]. The
nanogel coating protocol described previously was streamlined by substituting PEGoctovinylsulfone with PEG-4 maleimide (Creative PEGworks, Winston Salem, NC). This
modification greatly reduced the nanogel preparation time, since PEG-4 maleimide is
available commercially. After BSA and Tris capping, the chips were activated with EDC
and NHS[76] (Sigma Aldrich, St. Louis, MO), washed in water and dried with argon.

Capture and detection
Capture antibodies for p53 and MDM2 (R&D Systems, Minneapolis, MN ) were
printed by hand in triplicate onto the nanogel coating using a microarray pin (Arrayit
Corporation, Sunnyvale, CA) and allowed to dry 15 minutes. To form a flow chamber,
the chips were affixed, by a silicon gasket interface (Grace Biolabs, Bend, OR), onto a
standard glass slide (1” x 3”) fitted with two 1 mm holes. The flow chamber was inserted
onto the microscope stage, and the positions of the antibody fields were saved via
Metamorph software (Molecular Devices, Sunnyvale, California) using the white light
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image of the dried fields. The activated surface was quenched with Tris for 10 minutes
and washed with Tween-20.
The six-hour, semi-automated workflow went as follows. The flow chambers
(three technical replicates) were loaded with the protein sample (cell extract or a protein
standard), exposed for 2 h, washed with PBS, loaded with p53 and MDM2 biotinylated
detection antibody (only one or the other for protein-protein interaction detection),
exposed for 2 h, washed with PBS, loaded with Cy5-labeled streptavidin, exposed for 2 h,
and washed with PBS.
To measure the intrinsic limit of detection and dynamic range, we fabricated
microarray chips with biointinylated-BSA printed onto the surface. After washing with
Tween-20, flow chambers were loaded with different concentrations of Cy5-streptavidin.
After 2 hr exposure, the chips were washed with PBS, imaged, and analyzed.

Cell culture and protein extraction
In brief, we grew HCT116 cells under normal and 5-fluorouracil DNA damage
conditions, with three biological replicates per condition. Cells were harvested and
equalized for cell number. Cells were then lysed, and lysate was flowed onto microarrays
we had fabricated with p53 and MDM2 monoclonal capture antibody fields (three
technical replicates per microarray).
HCT116 cells were grown in DMEM + FBS medium and passaged into six flasks
(Sigma Aldrich, St. Louis, MO). Cells were grown to a confluence over 12 hours, then 25
μM 5-fluorouracil was added to three of the flasks. Cells were grown for an additional 12
hours and then trypsinized. Cells were rinsed twice in PBS and resuspended in lysis
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buffer (1 mM EDTA, 0.5% Triton X-100, 1 mM DTT, 150 mM NaCl, one Complete
protein extraction tablet (Roche, Basel, Switzerland)) and normalized to the same cell
concentration (107 cells / mL). Cells remained on ice for 15 minutes and were
centrifuged at 2000 x g for 5 minutes. Supernatant was used as input for the singlemolecule microarrays.

Imaging
Total internal reflection fluorescence (TIRF) imaging was performed at the
locations of the antibody fields, the images were processed by Metamorph and MATLAB
(Mathworks, Natick, MA)[76]. Molecule counts of fluorescence objects were obtained as
well as average fluorescence intensity per unit area. To average using ensemble
intensities, we used 400 x 400 pixel viewing areas from the center of the TIRF images
and calculated the average intensity over each pixel. To obtain digital counts we applied
custom software to identify discrete fluorescence objects, and summed the number of
objects
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SUPPORTING FIGURES

Figure S7. Using a set of paired, monoclonal antibodies, we performed single-molecule
microarray analysis on protein standards. Using digital analysis by fluorescence object
counting, we detected p53 and MDM2 down to the low picomolar range. This matches
the limit of detection using these antibodies in an optimized ELISA.
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APPENDIX TWO: DEEP SEQUENCING DETECTS RARE
GENETIC POLYMORPHISMS ASSOCIATED WITH
RESPIRATORY DISTRESS SYNDROME IN NEWBORNS
This appendix will contain a manuscript in preparation by Yue Yun and me. At
the time of this defense, the manuscript is still in early stages. For this collaborative
project we performed massively-paralleled Illumina DNA sequencing to find mutations
correlated with neonatal respiratory distress syndrome (RDS). Additionally this work
attempts to directly address the Rare Variants Hypothesis regarding heritability of
common diseases. To summarize the state of the project we:
Quantified and normalized DNA samples for 850 individuals using epMotion
robotics.
Prepared and submitted custom DNA libraries for over 50 lanes of pooled-sample
sequencing on the Illumina Genome Analyzer and HiSeq 2000.
Created

a

streamlined

software

package,

utilizing

existing

software

(SPLINTER[119]) and developing custom software for the identification of single
nucleotide polymorphisms (SNPs) from 54 billion nucleotides of data.
Submitted DNA samples to and analyzed results from Taqman and Sequenom
genotyping platforms for the 850 individuals.
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